NCCN Myeloproliferative Neoplasms Panel Members

Summary of the Guidelines Updates

Myeloproliferative Neoplasms:
- Workup (MPN-1)
- Diagnosis and Risk Stratification (MPN-2)

Myelofibrosis:
- Treatment for Low-Risk Myelofibrosis (MF-1)
- Treatment for Intermediate-Risk 1 (INT-1) Myelofibrosis (MF-2)
- Treatment for Intermediate-Risk 2 (INT-2) or High-Risk Myelofibrosis (MF-3)
- Management of MF-Associated Anemia (MF-4)
- Disease Progression to Advanced-Phase/AML (MF-5)
- Risk Stratification for Patients with Myelofibrosis (MF-A)
- Supportive Care (MF-B)
- 2013 IWG-MRT AND ELN Response Criteria for MF (MF-C)

Polycythemia Vera:
- Treatment for Low-Risk Polycythemia Vera (PV-1)
- Treatment for High-Risk Polycythemia Vera (PV-2)
- 2013 IWG-MRT AND ELN Response Criteria for PV (PV-A)

Essential Thrombocythemia:
- Treatment for Very Low-Risk and Low-Risk ET (ET-1)
- Treatment for Intermediate-Risk Essential Thrombocythemia (ET-2)
- Treatment for High-Risk Essential Thrombocythemia (ET-3)
- 2013 IWG-MRT AND ELN Response Criteria for ET (ET-A)

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See NCCN Categories of Evidence and Consensus.

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2017.
Updates in Version 2.2018 of the NCCN Guidelines for Myeloproliferative Neoplasms from Version 1.2018 include:

**MS-1**
- The discussion section was updated to reflect the changes in the algorithm.

Updates in Version 2.2018 of the NCCN Guidelines for Myeloproliferative Neoplasms from Version 2.2017 include:

- Polycythemia Vera (PV) and Essential Thrombocythemia (ET) are new algorithms for this version of the guidelines.
- **Global:** MPN-SAF TSS-10 items has been modified to MPN-SAF TSS (MPN-10)

**MPN-1**

**Workup:**
- "Bone marrow cytogenetics (blood, if bone marrow is inaspirable) (karyotype ± FISH)" (Also for MF-4, MF-5)
- "Molecular testing (blood) for JAK2 V617F mutation; if negative, test for CALR and MPL mutations (for patients with ET and MF) and JAK2 Exon 12 mutations (for patients with PV)"

**Footnotes:**
- "c": "Prognostic models incorporating other mutations have been proposed to identify patients who may be at risk of leukemic transformation. The role of next-generation sequencing (NGS) to identify high-risk mutations and the use of the Molecular International Prognostic Scoring System (MIPSS) is less well-established. NGS remains a research tool in many situations. However, it may be useful to establish clonality in selected circumstances (eg, "Triple Negative" non-mutated JAK2, MPL, and CALR)."
- "e": "Evaluation for allogeneic HCT is recommended for all patients with intermediate-2-risk (INT-2) and high-risk myelofibrosis and for patients with intermediate-1-risk (INT-1) myelofibrosis with low platelet counts and complex cytogenetics. Identification of “higher-risk” mutations may be helpful in the decision-making regarding allogeneic HCT for patients with primary myelofibrosis (PMF)." (Also for MF-2, MF-3)

**MPN-2**

**Footnotes:**
- "k": "Dynamic International Prognostic Scoring System (DIPSS)-Plus is preferred for the risk stratification of myelofibrosis; however, IPSS should be used at diagnosis. DIPSS can be used for risk stratification, if karyotyping is not available. See Risk Stratification for Patients with Myelofibrosis (MF-A). These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with Post-PV or Post-ET MF. Novel prognostic models are being developed for the risk stratification of post-PV and post-ET MF. See Discussion. (Also for MF-1, MF-2, MF-3)

**MF-1**

- The pathway off Symptomatic has been modified: "(Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b) or Hydroxyurea, if cytoreduction would be symptomatically beneficial"

**MF-2**

**Footnote:**
- "k": "Additional molecular marker monitoring including next-generation sequencing (NGS) is recommended for higher-risk patients with primary PMF." (Also for MF-3)
Updates in Version 1.2018 of the NCCN Guidelines for Myeloproliferative Neoplasms from Version 2.2017 include:

**MF-3**
- 8th column: "Advanced-stage MF/AML"

**Footnote:**
- "If a clinical trial is not available, other options should be considered" is new to the page.

**MF-4**
- "If a clinical trial is not available, other options should be considered"

**MF-A (1 of 2)**
- "These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with Post-PV or Post-ET MF. Novel prognostic models are being developed for the risk stratification of post-PV and post-ET MF." is new to the page and corresponds to International Prognostic Scoring System (IPSS). Also for MF-A (2 of 2).

**MF-B**
- "Consider G-CSF or GM-CSF for recurrent infections in patients with neutropenia. However, these should be used with caution in patients with enlarged spleen since the use of G-CSF or GM-CSF has been associated with splenic rupture" is new to the guideline under Hematopoietic growth factor therapy.

- 7th bullet modified: Consider cytoreductive therapy (eg, hydroxyurea) for thrombocytosis or leukocytosis. Consider cytoreductive therapy (eg, hydroxyurea) for hyperproliferative manifestations of PMF (thrombocytosis or leukocytosis).

**MPN-D (3 of 4)**
- ASXL1/ SRSF2/ IDH1/2: "The presence of at least 1 of these ‘adverse variants/mutations’ is associated with inferior overall survival (compared to other sequence variants/ mutations, or none) which was independent of age, IWG prognostic model for PV, and karyotype."

**Footnote:**
- Next-generation sequencing (NGS) remains a research tool in many situations. However, it may be useful to establish clonality in selected circumstances (eg, "Triple Negative" non-mutated JAK2, MPL, and CALR) is new to the page. Also for MPN-D (4 of 4).

**MPN-D (4 of 4)**
- "CALR mutation does not modify the IPSET score for predicting thrombosis in patients with ET"
- "The presence of at least 1 of these ‘adverse variants/mutations’ is associated with inferior overall survival (compared to other sequence variants/ mutations, or none) independent of age, IWG prognostic model for PV, and karyotype."" is new to the page.

**MPN-F (1 of 2)**
- "A-CBC with differential and comprehensive metabolic panel with uric acid and LDH must be performed before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated."
Updates in Version 1.2018 of the NCCN Guidelines for Myeloproliferative Neoplasms from Version 2.2017 include:

**MPN-G (1 of 2)**
- "Plateletpheresis may be indicated in patients with ET presenting with acute life-threatening thrombosis or severe bleeding" is new to the page for management of vascular events.

**MPN-G (2 of 2)**
- "Aspirin could be stopped and substituted by LMWH could be considered about two weeks before labor is expected."
- "Consider the use of prophylactic LMWH (subcutaneously) with low-dose aspirin plus prophylactic LMWH subcutaneously is recommended throughout pregnancy (to maintain hematocrit <45% in patients with PV) and for six weeks postpartum."
- "Consider stopping low-dose aspirin 1 to 2 weeks prior to delivery. LMWH should be stopped 12 hours to 24 hours before labor is expected. In patients taking LMWH, consultation with high-risk obstetrician and obstetric anesthesiologist is recommended regarding the optimal timing of discontinuation in preparation for an epidural prior to delivery.
- "In patients without prior bleeding or thrombotic complications, consider the use of LMWH instead of aspirin in the last two weeks of pregnancy (to maintain hematocrit <45% in patients with PV) and continued until six weeks post partum. The duration of LMWH post partum could be extended in high-risk pregnancy or in women who have undergone C-section."
- "If cytoreductive therapy is needed, interferons (interferon alfa-2b, peginterferon alfa-2a, and peginterferon alfa-2b) should be considered. Patients on hydroxyurea prior to pregnancy should be switched to interferons."

Footnotes:
- "4" modified:
  - Previous maternal major thromboembolic or major hemorrhagic complications.
  - Previous microcirculatory disturbances or presence of two or more hereditary thrombophilic factors.
  - Age >35 years
  - Platelet count during pregnancy >1000 x 10^9/l.
[WORKUP]

Suspicion of myeloproliferative neoplasms (MPN)

- H&P, including spleen size by palpation, evaluation of thrombotic/hemorrhagic events and cardiovascular risk factors
- CBC with differential
- Comprehensive metabolic panel with uric acid, lactate dehydrogenase (LDH), and liver function tests (LFTs)
- FISH or RT-PCR for BCR-ABL1 to exclude the diagnosis of CML; if BCR-ABL1-positive, See NCCN Guidelines for Chronic Myelogenous Leukemia
- Examination of blood smear
- Bone marrow aspirate and biopsy with trichrome and reticulin stain
- Bone marrow cytogenetics (blood, if bone marrow is inaspirable) (karyotype ± FISH)
- Molecular testing (blood) for JAK2 V617F mutation; if negative, test for CALR and MPL mutations (for patients with ET and MF) and JAK2 Exon 12 mutations (for patients with PV)
- Assessment of symptom burden using MPN Symptom Assessment form (MPN-SAF)
- Documentation of transfusion/medication history
- Human leukocyte antigen (HLA) testing, if considering allogeneic hematopoietic cell transplant (HCT)
- Serum erythropoietin (EPO) level
- Serum iron studies
- Coagulation tests to evaluate for acquired von Willebrand disease (VWD) and/or other coagulopathies in selected patients
  - Prothrombin time (PT), partial thromboplastin time (PTT), Fibrinogen
  - Plasma von Willebrand Factor Antigen (VWFA) measurement
  - Von Willebrand Ristocetin Cofactor (VWF:RCo) activity

[Diagnosis and Risk Stratification]

See MPN-2

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

See 2016 WHO Diagnostic Criteria for Primary Myelofibrosis (PMF). See (MPN-A).
See 2016 WHO Diagnostic Criteria for PV and ET. See (MPN-B).
Prognostic models incorporating other mutations have been proposed to identify patients who may be at risk of leukemic transformation. The role of next-generation sequencing (NGS) to identify high-risk mutations and the use of the Molecular International Prognostic Scoring System (MIPSS) is less well-established. NGS remains a research tool in many situations. However, it may be useful to establish clonality in selected circumstances (eg, "Triple Negative" non-mutated JAK2, MPL, and CALR). See MPN-D for a list of somatic mutations with prognostic significance in patients with MPN.
Assessment of symptoms (in provider's office) at baseline using MPN Symptom Assessment form (MPN-SAF) is recommended for all patients. See Assessment of Symptom Burden.

Evaluation for allogeneic HCT is recommended for all patients with intermediate-2-risk (INT-2) and high-risk myelofibrosis and for patients with intermediate-1-risk (INT-1) myelofibrosis with low platelet counts and complex cytogenetics. Identification of "higher-risk" mutations may be helpful in the decision-making regarding allogeneic HCT for patients with primary myelofibrosis (PMF). See Prognostic Significance of Mutations in MPN (MPN-D).

Patients undergoing high-risk surgical procedures and those with elevated platelet count and/or splenomegaly or unexplained bleeding.

An expanded panel including von Willebrand factor (VWF) antigen, Factor VIII activity, and VWF multimers may be useful under certain circumstances.
**DIAGNOSIS**

- **Primary myelofibrosis (PMF)**
- **Post-PV or Post-ET MF**

**RISK STRATIFICATION**

- **Low-risk (MF-1)**
- **Intermediate-risk 1 (INT-1) (MF-2)**
- **Intermediate-risk 2 (INT-2) and High-risk (MF-3)**

- **Polycythemia vera (PV)**
  - **Low-risk (PV-1)**
  - **High-risk (PV-2)**

- **Essential thrombocythemia (ET)**
  - **Intermediate-risk (ET-2)**
  - **High-risk (ET-3)**

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
TREATMENT FOR LOW-RISK MYELOFIBROSIS

Asymptomatic
Observation or Clinical trial

Monitor for signs and symptoms of disease progression every 3–6 months

Asymptomatic

Symptomaticb,c

Ruxolitinibd or Interferons (Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b) or Hydroxyurea, if cytoreduction would be symptomatically beneficial or Clinical trial

Monitor response and signs/symptoms of disease progression every 3–6 months

Response

No Response or Loss of response

INT-1, see MF-2, INT-2/High risk, see MF-3, and Advanced stage MF/AML, see MF-5

Disease progression

Continue treatmentd,h

Low risk Risk score = 0
IPSS
DIPSS and DIPSS-Plusa

Assess symptom burden using MPN-SAF TSS (MPN 10)b if not done previously

Symptomaticb,c

(a) Dynamic International Prognostic Scoring System (DIPSS)-Plus is preferred for the risk stratification of myelofibrosis; however, IPSS should be used at diagnosis. DIPSS can be used for risk stratification, if karyotyping is not available. See Risk Stratification for Patients with Myelofibrosis (MF-A). These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with Post-PV or Post-ET MF. Novel prognostic models are being developed for the risk stratification of post-PV and post-ET MF. See Discussion.

(b) See Assessment of Symptom Burden (MPN-C 3 of 3).

(c) See Supportive Care (MF-B).

(d) See Special Considerations for the Use of Ruxolitinib (MPN-F).

(e) Bone marrow aspirate and biopsy should be performed at diagnosis and as clinically indicated (if supported by increased symptoms and signs of progression).

(f) See 2013 IWG-MRT and ELN Response Criteria for MF (MF-C). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

(g) Disease progression to intermediate-risk 1 (INT-1) or intermediate-risk 2 (INT-2)/high-risk should be managed as outlined on MF-2 and MF-3. See MF-5 for disease progression to accelerated or blast phase MF or AML.

(h) Clinical benefit may not reach the threshold of the 2013 IWG Response Criteria and continuation of ruxolitinib is recommended based on the discretion of the clinician. See 2013 IWG-MRT and ELN Response Criteria for MF (MF-C).
### TREATMENT FOR INTERMEDIATE-RISK 1 (INT-1) MYELOFIBROSIS

**Intermediate-risk 1 (INT-1)**

- **Risk score:**
  - IPSS = 1
  - DIPSS-Plus = 1
  - DIPSS = 1 or 2a

**Assess symptom burden using MPN-SAF TSS-(MPN 10)b if not done previously**

**Observation or Ruxolitinibd if symptomaticc or Clinical trial or Allogeneic HCTi,j,k**

**Monitor responsef and signs/symptoms of disease progression every 3–6 monthsb,e,k**

- **Response**
  - Continue treatmentc,h
  - No Response or Loss of response
  - Disease progressiong

**INT-2/High risk, see MF-3, and Advanced stage MF/AML, see MF-5**

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

---

**a** Dynamic International Prognostic Scoring System (DIPSS)-Plus is preferred for the risk stratification of myelofibrosis; however, IPSS should be used at diagnosis. DIPSS can be used for risk stratification, if karyotyping is not available. See Risk Stratification for Patients with Myelofibrosis (MF-A). These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with Post-PV or Post-ET MF. Novel prognostic models are being developed for the risk stratification of post-PV and post-ET MF. See Discussion.

**b** See Assessment of Symptom Burden (MPN-C 3 of 3).

**c** See Supportive Care (MF-B).

**d** See Special Considerations for the Use of Ruxolitinib (MPN-F).

**e** Bone marrow aspirate and biopsy should be performed at diagnosis and as clinically indicated (if supported by increased symptoms and signs of progression).

**f** See 2013 IWG-MRT and ELN Response Criteria for MF (MF-C). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

**g** Disease progression to intermediate-risk 2 (INT-2)/high-risk should be managed as outlined on MF-3. See MF-5 for disease progression to accelerated or blast phase MF or AML.

**h** Clinical benefit may not reach the threshold of the IWG Response Criteria and continuation of ruxolitinib is recommended based on the discretion of the clinician. See 2013 IWG-MRT and ELN Response Criteria for MF (MF-C).

**i** Evaluation for allogeneic HCT is recommended for all patients with intermediate-2 risk (INT-2) and high-risk disease and for patients with intermediate-1 (INT-1) disease with low platelet counts or complex cytogenetics. Identification of “higher-risk” mutations may be helpful in the decision-making regarding allogeneic HCT for patients with PMF. See Prognostic Significance of Mutations in MPN (MPN-D).

**j** The selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

**k** Additional molecular marker monitoring including next-generation sequencing (NGS) is recommended for higher-risk patients with primary PMF. See Prognostic Significance of Mutations in MPN (MPN-D).
**TREATMENT FOR INTERMEDIATE-RISK 2 (INT-2) OR HIGH-RISK MYELOFIBROSIS**

**Intermediate-risk 2 (INT-2) Risk score:** (IPSS = 2, DIPSS-Plus = 2 or 3, DIPSS = 3 or 4)\(^a\)
- **Or High-risk Risk score:** (IPSS ≥ 3, DIPSS-Plus = 4 to 6, DIPSS = 5 or 6)\(^a\)

**Transplant candidate\(^l\)**
- **Platelets** ≤ 50K
- **Assess symptom burden using MPN-SAF TSS (MPN 10)\(^b\) if not done previously**
- **Ruxolitinib\(^d\) or Clinical trial**

**Not a transplant candidate\(^l\)**
- **Platelets** > 50K
- **Monitor response\(^f\) and signs/symptoms of disease progression every 3–6 months\(^b,e,k\)**

**Not a transplant candidate and symptomatic\(^c\) anemia only**
- **See Management of MF-Associated Anemia (MF-4)**

**Advanced-stage MF/AML (See MF-5)**
- **Response**
  - **No Response or Loss of response**
  - **Disease progression**
- **Continue treatment\(^d,h\)**

---

\(^a\)Dynamic International Prognostic Scoring System (DIPSS)-Plus is preferred for the risk stratification of myelofibrosis; however, IPSS should be used at diagnosis. DIPSS can be used for risk stratification, if karyotyping is not available. See Risk Stratification for Patients with Myelofibrosis (MF-A). These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with Post-PV or Post-ET MF. Novel prognostic models are being developed for the risk stratification of post-PV and post-ET MF. See Discussion.

\(^b\)See Assessment of Symptom Burden (MPN-C 3 of 3).

\(^c\)See Supportive Care (MF-B).

\(^d\)See Special Considerations for the Use of Ruxolitinib (MPN-F).

\(^e\)Bone marrow aspirate and biopsy should be performed at diagnosis and as clinically indicated (if supported by increased symptoms and signs of progression). See 2013 IWG-MRT and ELN Response Criteria for MF (MF-C). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

\(^f\)Clinical benefit may not reach the threshold of the IWG Response Criteria and continuation of ruxolitinib is recommended based on the discretion of the clinician. See 2013 IWG-MRT and ELN Response Criteria for MF (MF-C).

\(^g\)Evaluation for allogeneic HCT is recommended for all patients with intermediate-2 risk (INT-2) and high-risk disease and for patients with intermediate-1 (INT 1) disease with low platelet counts and complex cytogenetics. Identification of “higher-risk” mutations may be helpful in the decision-making regarding allogeneic HCT for patients with PMF. See Prognostic Significance of Mutations in MPN (MPN-D).

\(^h\)The selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

\(^i\)Additional molecular marker monitoring including next-generation sequencing (NGS) is recommended for higher-risk patients with primary PMF. See Prognostic Significance of Mutations in MPN (MPN-D).

\(^j\)If a clinical trial is not available, other options should be considered. See Discussion for further details.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
MANAGEMENT OF MF-ASSOCIATED ANEMIA

- H&P
- CBC with differential
- Examination of blood smear
- Bone marrow aspirate and biopsy with trichrome and reticulin stain\(^m, n\)
- Bone marrow cytogenetics (blood, if bone marrow is inaspirable) (karyotype ± FISH)\(^m, n\)
- Serum EPO level
- Rule out coexisting causes (eg, bleeding, iron, B12 or folate deficiency, hemolysis)

<table>
<thead>
<tr>
<th>Serum EPO &lt;500 mU/mL</th>
<th>Serum EPO ≥500 mU/mL</th>
</tr>
</thead>
</table>
| • Treat coexisting causes  
  › Replace iron, folate, B12, if needed  
  › Treat hemolysis if clinically indicated  
  › Red blood cell (RBC) transfusions (leuko-reduced)  
  › Supportive care\(^c\) | Erythropoiesis-stimulating agents (ESAs) (Darbepoetin alfa and Epoetin alfa) or Clinical trial |
| Response\(^f\) for or Loss of response | Continue treatment |

- Response\(^f\) for or Loss of response

<table>
<thead>
<tr>
<th>Serum EPO ≥500 mU/mL</th>
<th>Serum EPO ≥500 mU/mL</th>
</tr>
</thead>
</table>
| Danazol\(^o\) or  
  Alternative androgen  
  or (Lenalidomide\(^p\) or Thalidomide or Pomalidomide [category 3])  
  ± prednisone  
  or Clinical trial | Continue treatment\(^o, p\) |
| Response\(^f\) for or Loss of response | No response\(^f\) for or Loss of response |

\(^c\) See Supportive Care (MF-B).
\(^f\) See 2013 IWG-MRT and ELN Response Criteria for MF (MF-C). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

\(^m\) See 2016 WHO Diagnostic Criteria for Primary Myelofibrosis (PMF). See (MPN-A).

\(^n\) See 2016 WHO Diagnostic Criteria for PV and ET. See (MPN-B).

\(^o\) Prostate cancer screening for men and monitoring of liver function tests are recommended.

\(^p\) Presence of del(5q) is associated with better response rates with lenalidomide.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Disease progression to advanced-phase/AML

WORKUP
- Bone marrow aspirate and biopsy with trichrome and reticulin stain
- Bone marrow cytogenetics (blood, if bone marrow is inaspirable) (karyotype ± FISH)
- Flow cytometry
- Molecular testing for AML-associated mutations (See NCCN Guidelines for AML)

TREATMENT
- MF-accelerated phase (blasts 10%–19% in peripheral blood or bone marrow)
- MF blast phase/AML (blasts 20% in peripheral blood or bone marrow)

Transplant candidate
- Induce remission with hypomethylating agents (azacitidine or decitabine) or intensive induction chemotherapy
  (See NCCN Guidelines for AML) followed by allogeneic HCT

Clinical trial
- Hypomethylating agents (azacitidine or decitabine) or low-intensity induction chemotherapy
  (See NCCN Guidelines for AML)

Not a candidate for transplant

\(^1\)The selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

\(^2\)Ruxolitinib may be continued for the improvement of splenomegaly and other disease-related symptoms.

\(^3\)The WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].

\(^4\)Consider prophylaxis for tumor lysis syndrome (TLS). See Supportive Care (MF-B).
# NCCN Guidelines Version 2.2018
## Myelofibrosis

### RISK STRATIFICATION FOR PATIENTS WITH MYELOFIBROSIS

#### INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)\(^1,2\)

<table>
<thead>
<tr>
<th>PROGNOSTIC VARIABLE</th>
<th>POINTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>≤65 0  &gt;65 1</td>
</tr>
<tr>
<td>White blood cell count, x10^9/L</td>
<td>≤25 0  &gt;25 1</td>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td>≥10 0  &lt;10 1</td>
</tr>
<tr>
<td>Peripheral blood blast, %</td>
<td>&lt;1 0  ≥1 1</td>
</tr>
<tr>
<td>Constitutional symptoms, Y/N</td>
<td>N 0  Y 1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RISK GROUP</th>
<th>POINTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>0</td>
</tr>
<tr>
<td>Intermediate-1 (INT-1)</td>
<td>1</td>
</tr>
<tr>
<td>Intermediate-2 (INT-2)</td>
<td>2</td>
</tr>
<tr>
<td>High</td>
<td>≥3</td>
</tr>
</tbody>
</table>

\(^1\)These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with Post-PV or Post-ET MF. Novel prognostic models are being developed for the risk stratification of post-PV and post-ET MF. See Discussion.  

---

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**RISK STRATIFICATION FOR PATIENTS WITH MYELOFIBROSIS**

<table>
<thead>
<tr>
<th>PROGNOSTIC VARIABLE</th>
<th>POINTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, y</strong></td>
<td></td>
</tr>
<tr>
<td>≤65</td>
<td>0</td>
</tr>
<tr>
<td>&gt;65</td>
<td>1</td>
</tr>
<tr>
<td><strong>White blood cell count, x10^9/L</strong></td>
<td></td>
</tr>
<tr>
<td>≤25</td>
<td>0</td>
</tr>
<tr>
<td>&gt;25</td>
<td>1</td>
</tr>
<tr>
<td><strong>Hemoglobin, g/dL</strong></td>
<td></td>
</tr>
<tr>
<td>≥10</td>
<td>0</td>
</tr>
<tr>
<td>&lt;10</td>
<td>1</td>
</tr>
<tr>
<td><strong>Peripheral blood blast, %</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>≥1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Constitutional symptoms, Y/N</strong></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>0</td>
</tr>
<tr>
<td>Y</td>
<td>1</td>
</tr>
</tbody>
</table>

**RISK GROUP POINTS**

- Low: 0
- Intermediate-1 (INT-1): 1 or 2
- Intermediate-2 (INT-2): 3 or 4
- High: 5 or 6

---

**DIPSS-PLUS**

<table>
<thead>
<tr>
<th>PROGNOSTIC VARIABLE</th>
<th>POINTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIPSS low-risk</td>
<td>0</td>
</tr>
<tr>
<td>DIPSS intermediate-risk 1 (INT-1)</td>
<td>1</td>
</tr>
<tr>
<td>DIPSS intermediate-risk 2 (INT-2)</td>
<td>2</td>
</tr>
<tr>
<td>DIPSS high-risk</td>
<td>3</td>
</tr>
<tr>
<td>Platelets &lt;100 x 10^9/L</td>
<td>1</td>
</tr>
<tr>
<td>Transfusion need</td>
<td>1</td>
</tr>
<tr>
<td>Unfavorable karyotype*</td>
<td>1</td>
</tr>
</tbody>
</table>

**RISK GROUP POINTS**

- Low: 0
- Intermediate-1 (INT-1): 1
- Intermediate-2 (INT-2): 2 or 3
- High: 4 to 6

---

*Unfavorable karyotype: complex karyotype or sole or two abnormalities that include trisomy 8, 7/7q-, i(17q), 5/5q-, 12p-, inv(3), or 11q23 rearrangement.

---

1. These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with Post-PV or Post-ET MF. Novel prognostic models are being developed for the risk stratification of post-PV and post-ET MF. See **Discussion**.


---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**SUPPORTIVE CARE**

- Transfusion support
  - RBC transfusions for symptomatic anemia; platelet transfusions for thrombocytopenic bleeding or a platelet count <10,000 m³. In transplant candidates, use leukocyte-reduced blood products to prevent HLA alloimmunization and reduce the risk of (CMV) transmission.
  - Consider antifibrinolytic agents for bleeding that is refractory to transfusions.
  - Iron chelation could be considered for patients who have received >20 transfusions and/or ferritin >2500 ng/mL in low/intermediate-1-risk patients. However, the role of iron chelation remains unclear.
  - Antibiotic prophylaxis for recurrent infections is recommended. See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections. In splenectomized patients, antibiotic prophylaxis should be given per IDSA Guidelines.
  - Hematopoietic growth factor therapy
    - Consider G-CSF or GM-CSF for recurrent infections in patients with neutropenia. However, these should be used with caution in patients with an enlarged spleen since the use of G-CSF or GM-CSF has been associated with splenic rupture. See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections.
  - Consider cytoreductive therapy (eg, hydroxyurea) for hyperproliferative manifestations of PMF (thrombocytosis or leukocytosis).
  - Consider prophylaxis for tumor lysis syndrome (TLS) for patients undergoing induction therapy for advanced-stage MF or disease progression to AML.
    - Hydration and/or diuresis
    - Consider management of hyperuricemia with allopurinol or rasburicase.
    - Rasburicase should be considered as initial treatment in patients with rapidly increasing blast counts, high uric acid, and evidence of impaired renal function.
  - Counseling at baseline and throughout disease course for assessment for, identification of, and decreasing cardiovascular risk factors (eg, smoking, diet, exercise, thrombotic and hemorrhagic risk factors).

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### 2013 IWG-MRT AND ELN RESPONSE CRITERIA FOR MYELOFIBROSIS (MF)

<table>
<thead>
<tr>
<th>Response categories</th>
<th>Required criteria (for all response categories, benefit must last for ≥12 wk to qualify as a response)</th>
</tr>
</thead>
</table>
| **CR**              | **Bone marrow:**
|                     | Age-adjusted normocellularity; <5% blasts; ≤grade 1 MF and **Peripheral blood:** Hemoglobin ≥10 g/dL and < upper normal limit (UNL); Neutrophil count ≥1 x 10⁹/L and < UNL; Platelet count ≥100 x 10⁹/L and < UNL; <2% immature myeloid cells⁵ |
|                     | **Clinical:** Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis (EMH) |
| **PR**              | **Peripheral blood:** Hemoglobin ≥10 g/dL and < UNL; Neutrophil count ≥1 x 10⁹/L and < UNL; Platelet count ≥100 x 10⁹/L and < UNL; <2% immature myeloid cells⁵ |
|                     | **OR**
|                     | **Bone marrow:** Age-adjusted normocellularity; <5% blasts; ≤grade 1 MF and **Peripheral blood:** Hemoglobin ≥85, but <10 g/dL and < UNL; Neutrophil count ≥1 x 10⁹/L and < UNL; Platelet count ≥50, but <100 x 10⁹/L and < UNL; <2% immature myeloid cells⁵ |
|                     | **Clinical:** Resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH |


²These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### 2013 IWG-MRT AND ELN RESPONSE CRITERIA FOR MYELOFIBROSIS (MF)\(^1,2\)

<table>
<thead>
<tr>
<th>Response categories</th>
<th>Required criteria (for all response categories, benefit must last for ≥12 wk to qualify as a response)</th>
</tr>
</thead>
</table>
| Progressive disease\(^1\) | Appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin (LCM) or  
A ≥100% increase in palpable distance, below LCM, for baseline splenomegaly of 5–10 cm or  
A 50% increase in palpable distance, below LCM, for baseline splenomegaly of >10 cm or  
Leukemic transformation confirmed by a bone marrow blast count of ≥20% or  
A peripheral blood blast content of ≥20% associated with an absolute blast count of ≥1 x 10⁹/L that lasts for at least 2 weeks |
| Stable disease | Belonging to none of the above listed response categories |
| Relapse | No longer meeting criteria for at least confidence interval (CI) after achieving complete response (CR), partial response (PR), or  
CI or Loss of anemia response persisting for at least 1 month or  
Loss of spleen response persisting for at least 1 month |
| Clinical improvement (CI) | The achievement of anemia, spleen, or symptoms response without progressive disease or increase in severity of  
anemia, thrombocytopenia, or neutropenia\(^d\) |
| Anemia response | Transfusion-independent patients: a ≥2.0 g/dL increase in hemoglobin level\(^e\)  
Transfusion-dependent patients: becoming transfusion-independent\(^f\) |
| Spleen response\(^g\) | A baseline splenomegaly that is palpable at 5–10 cm, below the LCM, becomes not palpable\(^h\) or  
A baseline splenomegaly that is palpable at >10 cm below the LCM, decreases by ≥50%\(^h\)  
A baseline splenomegaly that is palpable at <5 cm below the LCM, not eligible for spleen response  
A spleen response requires confirmation by MRI or CT showing ≥35% spleen volume reduction |
| Symptoms response | A ≥50% reduction in the MPN-SAF TSS\(^i\) |

#### RECOMMENDATIONS FOR ASSESSING TREATMENT-INDUCED CYTOGENETIC AND MOLECULAR CHANGES

<table>
<thead>
<tr>
<th>Response categories</th>
<th>Required criteria</th>
</tr>
</thead>
</table>
| Cytogenetic remission | At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6-month window  
CR: Eradication of a pre-existing abnormality  
PR: ≥50% reduction in abnormal metaphases (partial response applies only to patients with at least 10 abnormal metaphases at baseline) |
| Molecular remission | Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6-month window  
CR: Eradication of a pre-existing abnormality  
PR: ≥50% decrease in allele burden (partial response applies only to patients with at least 20% mutant allele burden at baseline) |
| Cytogenetic/molecular relapse | Re-emergence of a pre-existing cytogenetic or molecular abnormality that is confirmed by repeat testing |


\(^2\)These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

**Note:** All recommendations are category 2A unless otherwise indicated.  
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

Continued
**FOOTNOTES**

**a** Baseline and posttreatment bone marrow slides are to be interpreted at one sitting by a central review process. Cytogenetic and molecular responses are not required for CR assignment.

**b** Grading of MF is according to the European classification. (Thiele et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128.) It is underscored that the consensus definition of a CR bone marrow is to be used only in those patients in which all other criteria are met, including resolution of leukoerythroblastosis. It should also be noted that it was a particularly difficult task for the working group to reach a consensus regarding what represents a complete histologic remission.

**c** Immature myeloid cells constitute blasts + promyelocytes + myelocytes + metamyelocytes + nucleated red blood cells. In splenectomized patients, <5% immature myeloid cells is allowed.

**d** See definitions of anemia response, spleen response, and progressive disease. Increase in severity of anemia constitutes the occurrence of new transfusion dependency or a ≥20 g/dL decrease in hemoglobin level from pretreatment baseline that lasts for at least 12 weeks. Increase in severity of thrombocytopenia or neutropenia is defined as a 2-grade decline, from pretreatment baseline, in platelet count or absolute neutrophil count, according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In addition, assignment to CI requires a minimum platelet count of ≥25 000 x 10⁹/L and absolute neutrophil count of ≥0.5 x 10⁹/L.

**e** Applicable only to patients with baseline hemoglobin of <10 g/dL. In patients not meeting the strict criteria for transfusion dependency at the time of study enrollment (see as follows), but in those who have received transfusions within the previous month, the pretransfusion hemoglobin level should be used as the baseline.

**f** Transfusion dependency before study enrollment is defined as transfusions of at least 6 units of packed red blood cells (PRBCs), in the 12 weeks prior to study enrollment, for a hemoglobin level of <85 g/dL, in the absence of bleeding or treatment-induced anemia. In addition, the most recent transfusion episode must have occurred in the 28 days prior to study enrollment. Response in transfusion-dependent patients requires absence of any PRBC transfusions during any consecutive “rolling” 12-week interval during the treatment phase, capped by a hemoglobin level of ≥85 g/dL.

**g** In splenectomized patients, palpable hepatomegaly is substituted with the same measurement strategy.

**h** Spleen or liver responses must be confirmed by imaging studies where a ≥35% reduction in spleen volume, as assessed by MRI or CT, is required. Furthermore, a ≥35% volume reduction in the spleen or liver, by MRI or CT, constitutes a response regardless of what is reported with physical examination.

**i** Symptoms are evaluated by the MPN-SAF TSS. The MPN-SAF TSS is assessed by the patients themselves and this includes fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Scoring is from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0–100 scale). Symptoms response requires ≥50% reduction in the MPN-SAF TSS.

**j** Progressive disease assignment for splenomegaly requires confirmation by MRI or CT showing a ≥25% increase in spleen volume from baseline. Baseline values for both physical examination and imaging studies refer to pretreatment baseline and not to posttreatment measurements.
### Polycythemia Vera

#### Low-risk (Age < 60 years and no prior history of thrombosis)<sup>a</sup>
- Monitor for new thrombosis or bleeding
- Manage cardiovascular risk factors (see MPN-G)
- Aspirin for vascular symptoms (81–100 mg/d)
- Phlebotomy (to maintain hematocrit <45%)<sup>b</sup>

#### TREATMENT FOR LOW-RISK POLYCYTHEMIA VERA

<table>
<thead>
<tr>
<th>Asymptomatic with no indications for cytoreductive therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>- New thrombosis or disease-related major bleeding</td>
</tr>
<tr>
<td>- Frequent and/or persistent need for phlebotomy, but with poor tolerance of phlebotomy</td>
</tr>
<tr>
<td>- Symptomatic or progressive splenomegaly</td>
</tr>
<tr>
<td>- Symptomatic thrombocytosis</td>
</tr>
<tr>
<td>- Progressive leukocytosis</td>
</tr>
<tr>
<td>- Progressive disease-related symptoms (eg, pruritus, night sweats, fatigue)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptomatic with potential indications for cytoreductive therapy&lt;sup&gt;e&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Continue aspirin with phlebotomy</td>
</tr>
<tr>
<td>- Initiate cytoreductive therapy See PV-2</td>
</tr>
<tr>
<td>- Post-PV MF, see MPN-2; Advanced phase MF/AML, see MF-5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disease progression to MF/AML&lt;sup&gt;f,g&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Evaluate for indications of cytoreductive therapy and monitor signs/symptoms of disease progression every 3–6 months or more frequently if clinically indicated&lt;sup&gt;c,d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Cytoreductive therapy is not recommended as initial treatment.
<sup>b</sup>Hematocrit <45% is based on the data from CYTOPV Study (Marchioli R et al. N Engl J Med 2013;368(1):22-33). There may be situations in which a lower hematocrit cutoff may be appropriate and it should be individualized, eg, 42% for female patients and/or progressive symptoms.
<sup>c</sup>See Assessment of Symptom Burden (MPN-C 3 of 3).
<sup>d</sup>Bone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.
<sup>f</sup>Diagnostic criteria for Post-ET or Post-PV MF. See (MPN-E).
<sup>g</sup>The WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
TREATMENT FOR HIGH-RISK POLYCYTHEMIA VERA

High-risk (Age ≥60 years and/or prior history of thrombosis)

- Monitor for new thrombosis or bleeding
- Manage cardiovascular risk factors (see MPN-G)
- Aspirin for vascular symptoms (81–100 mg/d)
- Phlebotomy (to maintain hematocrit <45%)b
- Hydroxyurea or Interferons (based on age and other patient specific variables)h

Monitor response1 and signs/symptoms of disease progression every 3–6 months or more frequently as clinically indicatedc,d

Adequate response

Potential indications for change of cytoreductive therapy:e
- Intolerance or resistance to hydroxyurea1 or interferon
- New thrombosis or disease-related major bleeding
- Frequent and/or persistent need for phlebotomy, but with poor tolerance of phlebotomy
- Symptomatic or progressive splenomegaly
- Symptomatic thrombocytosis
- Progressive leukocytosis
- Progressive disease-related symptoms (eg, pruritus, night sweats, fatigue)

Inadequate response or Loss of response

Disease progression to MF/AMLfg

Ruxolitinibk,l or Hydroxyurea if not previously used or Interferons if not previously used (Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b), or Clinical trial

Post-PV MF, see MPN-2; Advanced phase MF/AML, see MF-5

- Continue treatment

Hematocrit <45% is based on the data from CYTOPV Study (Marchioli R et al. N Engl J Med. 2013;368(1):22-33). There may be situations in which a lower hematocrit cutoff may be appropriate and it should be individualized, e.g. 42% for female patients and/or progressive symptoms.

Bone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.


SGene expression studies of patients with post-PV MF demonstrated a higher frequency of t(15;17), t(8;21), t(16;16), and inv(16). The WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), (8;21), (16;16), inv(16)].

Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b could be considered for younger patients or in pregnant patients in need of cytoreductive therapy or in those in need of cytoreductive therapy that defer hydroxyurea.

See 2013 IWG-MRT and ELN Response Criteria for (PV-A). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

Definition of intolerance/resistance to hydroxyurea (MPN-H).

See Special Considerations for the Use of Ruxolitinib (MPN-F).

Ruxolitinib is FDA approved for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### 2013 IWG-MRT and ELN RESPONSE CRITERIA FOR POLYCYTHEMIA VERA (PV)\(^1,2\)

<table>
<thead>
<tr>
<th>Complete remission</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong></td>
</tr>
<tr>
<td>Durable* resolution of disease-related signs including palpable hepatosplenomegaly, large symptoms improvement, † AND</td>
</tr>
<tr>
<td><strong>B</strong></td>
</tr>
<tr>
<td>Durable* peripheral blood count remission, defined as: hematocrit lower than 45% without phlebotomies; platelet count ≤400 x 10^9/L, WBC count &lt;10 x 10^9/L, AND</td>
</tr>
<tr>
<td><strong>C</strong></td>
</tr>
<tr>
<td>Without progressive disease, and absence of any hemorrhagic or thrombotic event, AND</td>
</tr>
<tr>
<td><strong>D</strong></td>
</tr>
<tr>
<td>Bone marrow histologic remission defined as the presence of age-adjusted normocellularity and disappearance of trilineage hyperplasia, and absence of &gt;grade 1 reticulin fibrosis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Partial remission</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong></td>
</tr>
<tr>
<td>Durable* resolution of disease-related signs including palpable hepatosplenomegaly, large symptoms improvement, † AND</td>
</tr>
<tr>
<td><strong>B</strong></td>
</tr>
<tr>
<td>Durable* peripheral blood count remission, defined as: hematocrit lower than 45% without phlebotomies; platelet count ≤400 x 10^9/L, WBC count &lt;10 x 10^9/L, AND</td>
</tr>
<tr>
<td><strong>C</strong></td>
</tr>
<tr>
<td>Without progressive disease, and absence of any hemorrhagic or thrombotic event, AND</td>
</tr>
<tr>
<td><strong>D</strong></td>
</tr>
<tr>
<td>Without bone marrow histologic remission defined as persistence of trilineage hyperplasia.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any response that does not satisfy partial remission</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Progressive disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transformation into post-PV myelofibrosis, myelodysplastic syndrome or acute leukemia</td>
</tr>
</tbody>
</table>

WBC: White blood cell count  
*Lasting at least 12 weeks  
†Large symptom improvement (≥10-point decrease) in MPN-SAF TSS.

---


\(^2\)These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.
TREATMENT FOR VERY LOW-RISK OR LOW-RISK ESSENTIAL THROMBOCYTHEMIAa

Very low-risk (Age ≤60 years, no JAK2 mutation, no prior history of thrombosis)b or Low-risk (Age ≤60 years, with JAK2 mutation, no prior history of thrombosis)b

- Monitor for new thrombosis, acquired VWD, and/or disease-related major bleeding
- Manage cardiovascular risk factors (see MPN-G)
- Aspirin c,d (81–100 mg/d) for vascular symptoms or Observation

Asymptomatic with no indications for cytoreductive therapy

Evaluate for indications of cytoreductive therapy and monitor signs/symptoms of disease progression every 3–6 months or more frequently if clinically indicated e,f

Symptomatic with potential indications for cytoreductive therapy g

Disease progression to MF/AMLn,h,i

- New thrombosis, acquired VWD, and/or disease-related bleeding
- Symptomatic or progressive splenomegaly
- Symptomatic thrombocytosis
- Progressive leukocytosis
- Progressive disease-related symptoms (eg, pruritus, night sweats, fatigue)
- Vasomotor/microvascular disturbances not responsive to aspirin (eg, headaches/cheek pain, erythromelalgia)

Continue aspirin or observation

Initiate cytoreductive therapy

See High-risk ET (ET-3)

Post-ET MF, see MPN-2; Advanced phase MF/AML, see MF-5

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

bCytoreductive therapy is not recommended as initial treatment.
cAspirin should be used with caution in patients with acquired VWD. Higher-dose aspirin may be appropriate in selected patients as clinically indicated. The risk and benefits of higher-dose aspirin must be weighed based on the presence of vasomotor symptoms versus the risk of bleeding.
dReport from a recent retrospective analysis (Alvarez-Larran et al. Haematologica 2016;101(8):926-31) suggests that the use of low-dose aspirin may not be beneficial in patients with low-risk CALR-mutated ET. However, at the present time, there is not enough evidence to recommend withholding aspirin for this group of patients.

eSee Assessment of Symptom Burden (MPN-C 3 of 3).
fBone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.
hDiagnostic criteria for Post-ET or Post-PV MF. See (MPN-E).
iThe WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].
NCCN Guidelines Version 2.2018
Essential Thrombocythemia

TREATMENT FOR INTERMEDIATE-RISK ESSENTIAL THROMBOCYTHEMIA

Intermediate-risk (Age >60 years, no JAK2 mutation, no prior history of thrombosis)

- Monitor for new thrombosis, acquired VWD, and/or disease-related major bleeding
- Manage cardiovascular risk factors (see MPN-G)
- Aspirin (81–100 mg/d) for vascular symptoms

Asymptomatic with no indications for cytoreductive therapy

• New thrombosis, acquired VWD, and/or disease-related major bleeding
• Symptomatic or progressive splenomegaly
• Symptomatic thrombocytosis
• Progressive leukocytosis
• Progressive disease-related symptoms (eg, pruritus, night sweats, fatigue)
• Vasomotor/microvascular disturbances not responsive to aspirin (eg, headaches/chest pain, erythromelalgia)

Disease progression to MF/AML

Symptomatic with potential indications for cytoreductive therapy

- New thrombosis, acquired VWD, and/or disease-related major bleeding
- Symptomatic or progressive splenomegaly
- Symptomatic thrombocytosis
- Progressive leukocytosis
- Progressive disease-related symptoms (eg, pruritus, night sweats, fatigue)
- Vasomotor/microvascular disturbances not responsive to aspirin (eg, headaches/chest pain, erythromelalgia)

Initiate cytoreductive therapy

Post-ET MF, see MPN-2; Advanced phase MF/AML, see MF-5

Continue aspirin

Bone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.


The WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].
TREATMENT FOR HIGH-RISK ESSENTIAL THROMBOCYTHEMIAa

- Monitor for new thrombosis, acquired VWD, and/or disease-related major bleeding
- Manage cardiovascular risk factors (see MPN-G)
- Aspirin (81–100 mg/d)c for vascular symptoms
- Hydroxyurea or Interferons (based on other patient-specific variables)l or Anagrelide

- Monitor response and signs/symptoms of disease progression every 3–6 months or more frequently as clinically indicatedef

- Adequate response
- Potential indications for change of cytoreductive therapy:9
  - Intolerance or resistance to hydroxyureak or interferon
  - New thrombosis, acquired VWD and/or disease-related major bleeding
  - Symptomatic or progressive splenomegaly
  - Symptomatic thrombocytosis
  - Progressive leukocytosis
  - Progressive disease-related symptoms (eg, pruritus, night sweats, fatigue)
  - Vasomotor/microvascular disturbances not responsive to aspirin (eg, headaches/chest pain, erythromelalgia)

- Hydroxyurea if not previously used or Interferons if not previously used (Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b) or Anagrelide if not previously used or Clinical trial

Disease progression to MF/AMLh,i

- Inadequate response or Loss of response

- Post-ET MF, see MPN-2; Advanced phase MF/AML, see MF-5

---

bAspirin should be used with caution in patients with acquired VWD. Higher-dose aspirin may be appropriate in selected patients as clinically indicated. The risk and benefits of higher-dose aspirin must be weighed based on the presence of vasomotor symptoms versus the risk of bleeding.

*See Assessment of Symptom Burden (MPN-C 3 of 3).

Bone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.


9Diagnostic criteria for Post-ET or Post-PV MF See (MPN-E).

The WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].

*See 2013 IWG-MRT and ELN Response Criteria for ET (ET-A). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

Definition of intolerance/resistance to hydroxyurea (MPN-H).

Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b could be considered for younger patients or in pregnant patients in need of cytoreductive therapy or in those in need of cytoreductive therapy that defer hydroxyurea.

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### Complete remission

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Durable(^*) resolution of disease-related signs including palpable hepatosplenomegaly, large symptoms improvement, † AND</td>
</tr>
<tr>
<td>B</td>
<td>Durable(^*) peripheral blood count remission, defined as: platelet count ≤400 x 10^9/L, WBC count &lt;10 x 10^9/L, absence of leukoerythroblastosis, AND</td>
</tr>
<tr>
<td>C</td>
<td>Without signs of progressive disease, and absence of any hemorrhagic or thrombotic events, AND</td>
</tr>
<tr>
<td>D</td>
<td>Bone marrow histologic remission defined as disappearance of megakaryocyte hyperplasia and absence of &gt;grade 1 reticulin fibrosis.</td>
</tr>
</tbody>
</table>

### Partial remission

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Durable(^*) resolution of disease-related signs including palpable hepatosplenomegaly, and large symptoms improvement, AND</td>
</tr>
<tr>
<td>B</td>
<td>Durable(^*) peripheral blood count remission, defined as: platelet count ≤400 x 10^9/L, WBC count &lt;10 x 10^9/L, absence of leukoerythroblastosis, AND</td>
</tr>
<tr>
<td>C</td>
<td>Without signs of progressive disease, and absence of any hemorrhagic or thrombotic events, AND</td>
</tr>
<tr>
<td>D</td>
<td>Without bone marrow histologic remission, defined as the persistence megakaryocyte hyperplasia</td>
</tr>
</tbody>
</table>

**No response**

Any response that does not satisfy partial remission

**Progressive disease**

Transformation into PV, post-ET myelofibrosis, myelodysplastic syndrome or acute leukemia

---

WBC White Blood Count
\(^*\)Lasting at least 12 weeks
\(^\dagger\)Large symptom improvement (≥10-point decrease) in MPN-SAF TSS.

---


2These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

---

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
2016 WHO DIAGNOSTIC CRITERIA FOR PRIMARY MYELOFIBROSIS

WHO prePMF Criteria

(Diagnosis of prePMF requires meeting all 3 major criteria, and at least 1 minor criterion)

- Major criteria
  - Megakaryocytic proliferation and atypia, without reticulin fibrosis >grade 1, accompanied by increased age-adjusted BM cellularity, granulocytic proliferation, and often decreased erythropoiesis
  - Not meeting WHO criteria for BCR-ABL1+ CML, PV, ET, myelodysplastic syndromes, or other myeloid neoplasms
  - Presence of JAK2, CALR, or MPL mutation or in the absence of these mutations, presence of another clonal marker, or absence of minor reactive BM reticulin fibrosis

- Minor criteria
  - Presence of at least one of the following, confirmed in 2 consecutive determinations:
    - Anemia not attributed to a comorbid condition
    - Leukocytosis ≥11 x 10^9/L
    - Palpable splenomegaly
    - LDH increased to above upper normal limit of institutional reference range

WHO Overt PMF Criteria

(Diagnosis of overt PMF requires meeting all 3 major criteria, and at least 1 minor criterion)

- Major criteria
  - Presence of megakaryocytic proliferation and atypia, accompanied by either reticulin and/or collagen fibrosis grades 2 or 3
  - Not meeting WHO criteria for ET, PV, BCR-ABL1+ CML, myelodysplastic syndromes, or other myeloid neoplasms
  - Presence of JAK2, CALR, or MPL mutation or in the absence of these mutations, presence of another clonal marker, or absence of reactive myelofibrosis

- Minor criteria
  - Presence of at least one of the following, confirmed in 2 consecutive determinations:
    - Anemia not attributed to a comorbid condition
    - Leukocytosis ≥11 x 10^9/L
    - Palpable splenomegaly
    - LDH increased to above upper normal limit of institutional reference range
    - Leukoerythroblastosis

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
2016 WHO DIAGNOSTIC CRITERIA FOR PRIMARY MYELOFIBROSIS¹

2016 WHO GRADING OF MYELOFIBROSIS

WHO Myelofibrosis Grading

- MF-0
  - Scattered linear reticulin with no intersections (crossovers) corresponding to normal BM
- MF-1
  - Loose network of reticulin with many intersections, especially in perivascular areas
- MF-2
  - Diffuse and dense increase in reticulin with extensive intersections, occasionally with focal bundles of thick fibers mostly consistent with collagen, and/or focal osteosclerosis*
- MF-3
  - Diffuse and dense increase in reticulin with extensive intersections and course bundles of thick fibers consistent with collagen, usually associated with osteosclerosis*


*In grades MF-2 or MF-3 an additional trichrome stain is recommended.
2016 WHO DIAGNOSTIC CRITERIA FOR POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA

Polycythemia Vera (PV)
[Diagnosis requires meeting either all 3 major criteria, or the first 2 major criteria and the minor criterion2]

- Major criteria
  - Hemoglobin >16.5 g/dL in men, >16.0 g/dL in women
  - OR
    - Hematocrit >49% in men, >48% in women
  - OR
    - Increased red cell mass (RCM)3
  - Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes (differences in size)
  - Presence of JAK2 V617F or JAK2 exon 12 mutation

- Minor criteria
  - Subnormal serum EPO level

Essential Thrombocythemia (ET)
[Diagnosis requires meeting all 4 major criteria or the first 3 major criteria and the minor criterion]

- Major criteria
  - Platelet count ≥450 x 10^9/L
  - Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant increase or left shift in neutrophil granulopoiesis or erythropoiesis and very rarely minor (grade 1) increase in reticulin fibers
  - Not meeting WHO criteria for BCR-ABL1+ CML, PV, PMF, myelodysplastic syndromes, or other myeloid neoplasms
  - Presence of JAK2, CALR, or MPL mutation

- Minor criterion
  - Presence of a clonal marker or absence of evidence for reactive thrombocytosis

---


2 Criterion number 2 (BM biopsy) may not be required in cases with sustained absolute erythrocytosis; hemoglobin levels >18.5 g/dL in men (hematocrit, 55.5%) or >16.5 g/dL in women (hematocrit, 49.5%) if major criterion 3 and the minor criterion are present. However, initial myelofibrosis (present in up to 20% of patients) can only be detected by performing a BM biopsy; this finding may predict a more rapid progression to overt myelofibrosis (post-PV MF).

3 More than 25% above mean normal predicted value.
ASSESSMENT OF SYMPTOM BURDEN

- Assessment of symptoms (in provider’s office) at baseline and monitoring symptom status (stable, improved, or worsening) during the course of treatment is recommended for all patients.
- Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) is recommended for the assessment of symptom burden at baseline (See MPN-C, 2 of 3).
- The 2013 IWG-MRT and ELN Response Criteria for MF recommend the use of MPN-SAF Total Symptom Score (MPN-SAF TSS; MPN 10) for monitoring symptom status during the course of treatment (See MPN-C 3 of 3).
- MPN-SAF TSS is assessed by the patients themselves. Scoring is from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0–100 scale).
- Symptom response requires ≥50% reduction in the MPN-SAF TSS. A symptom response <50% may be clinically meaningful and justify continued use of ruxolitinib.
- Changes in symptom status could be a sign of disease progression. Therefore, change in symptom status should prompt evaluation of treatment efficacy and/or disease status.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM (MPN-SAF)

(Recommended for assessment of symptom burden at baseline)

Circle the one number that describes, during the past week, how much difficulty you have had with each of the following symptoms.

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Score Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filling up quickly when you eat (early satiety)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Inactivity</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Problems with headaches</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Problems with concentration-compared to prior to my MPD</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Dizziness/Vertigo/Lightheadedness</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Numbness/Tingling (in my hands and feet)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Difficulty sleeping</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Depression or sad mood</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Problems with sexual desire or function</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Cough</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Night sweats</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Itching (pruritus)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Bone pain (diffuse not joint pain or arthritis)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Fever (&gt;100 F)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Daily)</td>
</tr>
<tr>
<td>Unintentional weight loss last 6 months</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>What is your overall quality of life?</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (As bad as it can be)</td>
</tr>
</tbody>
</table>


**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
## MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM

**TOTAL SYMPTOM SCORE (MPN-SAF TSS; MPN 10)**

(Recommended for monitoring symptoms during the course of treatment)

<table>
<thead>
<tr>
<th>Symptom</th>
<th>1 to 10 (0 if absent) ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your WORST level of fatigue during past 24 hours</td>
<td>(No Fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Filling up quickly when you eat (early satiety)</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Inactivity</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Problems with concentration-compared to prior to my MPD</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Numbness/Tingling (in my hands and feet)</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Night sweats</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Itching (pruritus)</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Bone pain (diffuse not joint pain or arthritis)</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Fever (&gt;100 F)</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Daily)</td>
</tr>
<tr>
<td>Unintentional weight loss last 6 months</td>
<td>(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
</tbody>
</table>

Circle the one number that describes, during the past week, how much difficulty you have had with each of the following symptoms.

---

PROGNOSTIC SIGNIFICANCE OF MUTATIONS IN MPN

<table>
<thead>
<tr>
<th>Mutated Gene</th>
<th>Primary Myelofibrosis (PMF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK2V617F</td>
<td>Intermediate prognosis and higher risk of thrombosis compared to patients with CALR mutation</td>
</tr>
<tr>
<td>MPLW515L/K</td>
<td>Intermediate prognosis and higher risk of thrombosis compared to patients with CALR mutation</td>
</tr>
<tr>
<td>CALR</td>
<td>Improved survival compared to JAK2 mutation and &quot;triple-negative&quot; PMF&lt;sup&gt;1-4&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Lower risk of thrombosis compared to JAK2 mutation&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>CALR Type 1/Type 1-like</td>
<td>Improved overall survival compared to CALR type 2/type 2-like and JAK2 V617F mutation&lt;sup&gt;5-8&lt;/sup&gt;</td>
</tr>
<tr>
<td>&quot;Triple Negative&quot;</td>
<td>Inferior leukemia-free survival compared to patients with JAK2- and/or CALR-mutated PMF&lt;sup&gt;1-3&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Inferior overall survival compared to patients with CALR-mutated PMF&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>ASXL1</td>
<td>Independently associated with inferior overall survival&lt;sup&gt;6&lt;/sup&gt; and leukemia-free survival&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td>EZH2</td>
<td>Independently associated with inferior overall survival&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td>IDH1/2</td>
<td>Independently associated with inferior leukemia-free survival&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td>SRSF2</td>
<td>Independently associated with inferior overall survival and leukemia-free survival&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td>Combined CALR and ASXL1 status</td>
<td>Survival longest for CALR(+)ASXL1(-) patients (median 10.4 years)</td>
</tr>
<tr>
<td></td>
<td>and shortest in CALR(-)ASXL1(+) patients (median 2.3 years)&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Intermediate survival (median 5.8 years) for CALR(+)ASXL1(+) or CALR(-)ASXL1(-) patients&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td>TP53</td>
<td>Associated with leukemic transformation&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>1</sup>ASXL1 mutation retains prognostic significance for inferior overall survival independent of IPSS or DIPSS-Plus risk score.

<sup>2</sup>The CALR/ASXL1 mutation status was DIPSS-Plus independent (<i>P < .0001</i>) and effective in identifying low-/intermediate-1-risk patients with shorter (median, 4 years) or longer (median 20 years) survival and high-/intermediate-2-risk patients with shorter (median, 2.3 years) survival.

See references on MPN-D (2 of 4)
REFERENCES


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### PROGNOSTIC SIGNIFICANCE OF MUTATIONS IN MPN

<table>
<thead>
<tr>
<th>Mutated Gene</th>
<th>Polycythemia Vera (PV)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASXL1/ SRSF2/ IDH1/2</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
<td>The presence of at least 1 of these ‘adverse variants/mutations’ is associated with inferior overall survival (compared to other sequence variants/mutations, or none) independent of age, IWG prognostic model for PV, and karyotype.&lt;sup&gt;2&lt;/sup&gt; Adverse variants/mutations also affected myelofibrosis-free survival.</td>
</tr>
<tr>
<td><strong>JAK2 exon 12 mutation</strong></td>
<td>Patients with JAK2 exon 12-mutated PV exhibit younger age, increased mean hemoglobin/hematocrit, and lower mean white blood cell and platelet counts at diagnosis compared to those with JAK2 V617F-mutated PV. However, both JAK2 mutations are associated with similar rates of thrombosis, evolution to myelofibrosis or leukemia, and death.&lt;sup&gt;3,4&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>1</sup>Next-generation sequencing (NGS) remains a research tool in many situations. However, it may be useful to establish clonality in selected circumstances (eg, "Triple Negative" non-mutated JAK2, MPL, and CALR).


---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
## PROGNOSTIC SIGNIFICANCE OF MUTATIONS IN MPN

<table>
<thead>
<tr>
<th>Mutated Gene</th>
<th>Essential Thrombocythemia (ET)</th>
</tr>
</thead>
</table>
| **CALR**     | Lower-risk of thrombosis compared to JAK2-mutated ET<sup>1-3</sup>  
                No difference in overall survival or myelofibrotic or leukemic transformation compared to JAK2-mutated ET<sup>1-3</sup>  
                **CALR** mutation does not modify the IPSET score for predicting thrombosis in patients with ET<sup>4</sup> |
| **TP53**     | Associated with inferior leukemia-free survival in multivariate analysis<sup>5</sup> |
| **SH2B3/IDH2/U2AF1/SF3B1/EZH2/TP53**<sup>6</sup> | The presence of at least 1 of these "adverse variants/mutations" is associated with inferior overall survival (compared to other sequence variants/ mutations, or none) independent of age and karyotype<sup>7</sup>  
                Adverse variants/mutations also affect myelofibrosis-free survival<sup>7</sup> |

---


<sup>2</sup>Rumi et al. JAK2 or **CALR** mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014 Mar 6;123(10):1544-51.


<sup>6</sup>Next-generation sequencing (NGS) remains a research tool in many situations. However, it may be useful to establish clonality in selected circumstances (eg, "Triple Negative" non-mutated JAK2, **MPL**, and **CALR**).


---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

*Version 2.2018, 09/07/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.*
**IWG-MRT DIAGNOSTIC CRITERIA FOR POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL (ET) MYELOFIBROSIS**

Criteria for post-PV myelofibrosis

**Required criteria:**
- Documentation of a previous diagnosis of PV as defined by the WHO criteria
- Bone marrow fibrosis grade 2–3 (on 0–3 scale) or grade 3–4 (on 0–4 scale)

**Additional criteria (two are required):**
- Anemia or sustained loss of requirement of either phlebotomy (in the absence of cytoreductive therapy) or cytoreductive treatment for erythrocytosis
- A leukoerythroblastic peripheral blood picture
- Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥5 cm (distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly
- Development of ≥1 of three constitutional symptoms: >10% weight loss in 6 months, night sweats, unexplained fever (>37.5°C)

Criteria for post-ET myelofibrosis

**Required criteria:**
- Documentation of a previous diagnosis of ET as defined by the WHO criteria
- Bone marrow fibrosis grade 2–3 (on 0–3 scale) or grade 3–4 (on 0–4 scale)

**Additional criteria (two are required):**
- Anemia and ≥2 g/dL decrease from baseline hemoglobin level
- A leukoerythroblastic peripheral blood picture
- Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥5 cm (distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly
- Increased LDH (above reference level)
- Development of ≥1 of 3 constitutional symptoms: >10% weight loss in 6 months, night sweats, unexplained fever (>37.5°C)

---

5 Grade 2–3 according to the European classification: diffuse, often coarse fiber network with no evidence of collagenization (negative trichrome stain) or diffuse, coarse fiber network with areas of collagenization (positive trichrome stain). Grade 3–4 according to the standard classification: diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis or diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis.
6 Below the reference range for appropriate age, sex, gender, and altitude considerations.
SPECIAL CONSIDERATIONS FOR THE USE OF RUXOLITINIB

• CBC with differential and comprehensive metabolic panel with uric acid and LDH must be performed before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.
• A baseline MPN-SAF TSS (MPN-10) (prior to initiation of therapy) is recommended to monitor symptoms during the course of therapy.
• Symptoms may return to pretreatment levels over a period of approximately one week following discontinuation or interruption of ruxolitinib. Consider tapering the dose of ruxolitinib gradually, when discontinuing or interrupting therapy with ruxolitinib for reasons other than thrombocytopenia or neutropenia.
• Monitor spleen size either by palpation or imaging.

Myelofibrosis (MF)

Dosing and administration:
The recommended initial dosing of ruxolitinib (as described in the full prescribing information) is dependent on the patient's baseline platelet counts. However, certain clinical situations may support initiation of ruxolitinib at a lower dose with subsequent dose adjustments.

- 50 X 10^9/L to less than 100 X 10^9/L: 5 mg twice daily
- 100 X 10^9/L - 200 X 10^9/L: 15 mg twice daily
- >200 X 10^9/L: 20 mg twice daily

Dose modifications based on insufficient response:
- Increase dose as tolerated, at 4-week intervals, in 5 mg twice daily increments to a maximum of 10 mg twice daily (if <100 x 10^9/L)/ 25 mg twice daily (if >100 x 10^9/L).
- Doses should not be increased during the first 4 weeks of therapy and not more frequently than every 2 weeks.
- Consider dose increases in patients who meet all of the following conditions. Discontinue if no response or improvement of symptoms after 6 months.
  - Failure to achieve a 50% reduction in palpable splenomegaly or symptom improvement or a 35% reduction in spleen volume as measured by CT or MRI. Inadequate reduction in splenomegaly is determined by the treating clinician. Less than 50% reduction in palpable splenomegaly may be clinically meaningful and justify continued use of ruxolitinib.
  - Platelet count >125 X 10^9/L at 4 weeks and platelet count never <100 X 10^9/L; ANC Levels greater than 0.75 X 10^9/L.

Polycythemia Vera (PV)

Dosing and administration:
The recommended initial dosing of ruxolitinib (as described in the full prescribing information) is 10 mg twice daily. Doses may be titrated based on safety and efficacy.

Dose modifications based on insufficient response:
Dose modification should be based on the efficacy of ruxolitinib (eg, improving phlebotomy burden, symptom burden, and splenomegaly) versus toxicity.

- Doses may be increased as tolerated in 5 mg twice-daily increments to a maximum of 25 mg twice daily.
- Doses should not be increased during the first 4 weeks of therapy and not more frequently than every two weeks.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

See MPN-F (2 of 2) for Hematologic Toxicities
Dose Modifications for Hematologic and Non-Hematologic Toxicities:

**Hematologic Toxicities**

Thrombocytopenia should be managed by dose reduction or dose interruption (at the discretion of treating clinician based on clinical parameters). Platelet transfusions may be necessary. Management of anemia may require blood transfusions and/or dose modifications. Severe neutropenia (ANC less than 0.5 x 10^9/L) was generally reversible by withholding ruxolitinib. Ruxolitinib may be restarted at prior dose or with subsequent modifications if necessary after recovery of the hematologic parameter(s) to acceptable levels. Monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. See prescribing information for dose modifications for hematologic toxicities.

**Non-Hematologic Toxicities**

**Lipid Elevations**

Ruxolitinib has been associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Assess lipid parameters approximately 8–12 weeks following initiation of ruxolitinib. Monitor and treat according to clinical guidelines for the management of hyperlipidemia.

**Renal Impairment**

Dose reduction is recommended for patients with moderate (CrCl 30–59 mL/min) or severe renal impairment (CrCl 15–29 mL/min) with a platelet count between 50 x 10^9/L and 150 x 10^9/L. See prescribing information for dose adjustments related to renal impairment.

**Hepatic Impairment**

Dose reduction is recommended for patients with any degree of hepatic impairment and platelet count between 50 x 10^9/L and 150 x 10^9/L. See prescribing information for dose adjustments related to hepatic impairment.

**Infections**

Ruxolitinib is associated with a potentially increased risk of opportunistic infections. Patients should be assessed for the risk of developing serious bacterial, mycobacterial, fungal, and viral infections. Patients receiving ruxolitinib should be carefully observed for signs and symptoms of infections. Appropriate treatment should be initiated promptly to resolve active serious infections before initiating ruxolitinib therapy.

**Tuberculosis**

Tuberculosis infection has been reported in patients receiving ruxolitinib. Patients should be evaluated for tuberculosis risk factors, and those at higher risk should be tested for latent infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended prior to initiating ruxolitinib for patients with evidence of active or latent tuberculosis.

**Hepatitis B**

Increases in Hepatitis B viral load (HBV-DNA titer) with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic HBV infections treated with ruxolitinib. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.

**PML and Herpes Zoster**

Progressive multifocal leukoencephalopathy (PML) and herpes zoster virus (HZV) infection have been reported in patients treated with ruxolitinib. If PML is suspected, ruxolitinib should be discontinued. Patients with suspected HZV infection should be treated and monitored according to clinical guidelines. Herpes zoster vaccine is not recommended for patients receiving ruxolitinib.

**Non-Melanoma Skin Cancer**

Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred in patients treated with ruxolitinib. Perform periodic skin examinations.

---

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
SPECIAL CONSIDERATIONS IN THE TREATMENT OF POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)

Management of Vascular Events

- **Thrombosis**
  - The use of clinically appropriate anticoagulant therapy (e.g., low-molecular-weight heparin [LMWH], direct oral anticoagulant, warfarin) is recommended for patients with active thrombosis. The initial use of anticoagulant therapy for the prevention and treatment of thrombosis should be based on the current American College of Chest Physicians (ACCP) Guidelines.¹
  - There are no data to guide the selection or appropriate duration of anticoagulation with or without antiplatelet therapy in patients with PV or ET. The duration of anticoagulant therapy is dependent on the severity of the thrombotic event (e.g., abdominal vein thrombosis vs. deep vein thrombosis), degree of disease control, and assessment of likelihood of recurrence after cessation of anticoagulant therapy.
  - Assess the need for cytoreductive therapy (if not done before) and initiate cytoreductive therapy (to maintain hematocrit <45% in patients with PV) if necessary. In the presence of inadequate response, consider intensification of therapy or switch to an alternate agent. The value of cytoreduction in reducing future vascular events has not been studied in a prospective, randomized, controlled trial.
  - Plateletpheresis may be indicated in patients with ET presenting with acute life-threatening thrombosis or severe bleeding.

- **Bleeding**
  - Rule out other potential causes and treat coexisting causes as necessary.
  - Aspirin should be withheld until bleeding is under control. Consider the use of appropriate cytoreductive therapy to normalize platelet counts.
  - Coagulation tests to evaluate for acquired VWD and/or other coagulopathies are recommended for patients undergoing high-risk surgical procedures and those with elevated platelet count and/or splenomegaly or unexplained bleeding (see MPN-1).
  - In unanticipated gastrointestinal (GI) bleeding, particularly in the setting of splenomegaly, portal hypertension, and gastric varices, special consultation (for endoscopic evaluation) with a hepatologist or a GI specialist is recommended.

**Surgery**

- Multi-disciplinary management with surgical and perioperative medical teams (e.g., review of bleeding and thrombosis history; medication list) is recommended.
- Emergency surgery should be performed as necessary with close postoperative surveillance for the symptoms of arterial or venous thrombosis and bleeding.
- Patients with PV and ET are at higher risk for bleeding despite optimal management. The thrombotic and bleeding risk of the surgical procedure (e.g., orthopedic and cardiovascular surgery) should be strongly considered prior to elective surgery.
- Thrombosis and bleeding risk should be well controlled (normalization or near-normalization CBC without causing prohibitive cytopenias) prior to performing elective surgery (particularly for orthopedic surgeries or any surgical procedures associated with prolonged immobilization) with the use of appropriate anticoagulant prophylaxis and cytoreductive therapy. If surgery is associated with a high risk for venous thromboembolism (e.g., cancer surgery, splenectomy, orthopedic and cardiovascular surgery), extended prophylaxis with LMWH should be considered. Prophylaxis with aspirin may be considered following vascular surgery.

See references on MPN-G 2 of 2

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
SPECIAL CONSIDERATIONS IN THE TREATMENT OF POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)

Surgery (continued)
• In patients with PV, hematocrit should be controlled for 3 months before elective surgery (normalization or near-normalization of CBC). Additional phlebotomy may also be necessary to maintain hematocrit <45% prior to performing elective surgery.
• Aspirin should be discontinued one week prior to surgical procedure and restarted 24 hours after surgery or when considered acceptable depending on the bleeding risk.
• Anticoagulant therapy should be withheld (based on the half-life/type of agent) prior to surgery and restarted after surgery when considered acceptable depending on the bleeding risk.
• Cytoreductive therapy could be continued throughout the perioperative period, unless there are unique contraindications expressed by the surgical team.

Pregnancy
• Pre-conception meeting and evaluation by high-risk obstetrician should be considered.
• Low-risk pregnancy: Low-dose aspirin (50–100 mg/d) is recommended throughout pregnancy (to maintain hematocrit <45% in patients with PV) and for six weeks postpartum. Aspirin could be stopped and LMWH could be considered about two weeks before labor is expected.
• High-risk pregnancy: Consider the use of prophylactic LMWH (subcutaneously) with low-dose aspirin throughout pregnancy (to maintain hematocrit <45% in patients with PV) and for six weeks postpartum.
• Consider stopping low-dose aspirin 1 to 2 weeks prior to delivery. LMWH should be stopped 12 hours to 24 hours before labor is expected. In patients taking LMWH, consultation with high-risk obstetrician and obstetric anesthesiologist is recommended regarding the optimal timing of discontinuation in preparation for an epidural prior to delivery.
• In patients without prior bleeding or thrombotic complications, consider the use of LMWH instead of aspirin in the last two weeks of pregnancy (to maintain hematocrit <45% in patients with PV) and continued until six weeks post partum. The duration of LMWH post partum could be extended in high-risk pregnancy or in women who have undergone C-section.
• If cytoreductive therapy is needed, interferons (interferon alfa-2b, peginterferon alfa-2a, and peginterferon alfa-2b) should be considered. Patients on hydroxyurea prior to pregnancy should be switched to interferons.
• Hydroxyurea is excreted in breastmilk and should be avoided in women who are breast feeding.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### Definition of Resistance/Intolerance to Hydroxyurea¹

<table>
<thead>
<tr>
<th>Myeloproliferative Neoplasm</th>
<th>Definition of Resistance/Intolerance to Hydroxyurea</th>
</tr>
</thead>
</table>
| Polycythemia vera          | 1. Need for phlebotomy to keep hematocrit <45% after 3 months of at least 2 g/d of hydroxyurea, OR  
2. Uncontrolled myeloproliferation (ie, platelet count >400 x 10⁹/L AND WBC count >10 x 10⁹/L) after 3 months of at least 2 g/d of hydroxyurea, OR  
3. Failure to reduce massive* splenomegaly by >50% as measured by palpation OR failure to completely relieve symptoms related to splenomegaly after 3 months of at least 2 g/d of hydroxyurea, OR  
4. Absolute neutrophil count <1.0 x 10⁹/L OR platelet count <100 x 10⁹/L OR hemoglobin <10 g/dL at the lowest dose of hydroxyurea required to achieve a complete or partial clinicohematologic response,† OR  
5. Presence of leg ulcers or other unacceptable hydroxyurea-related nonhematologic toxicities, such as mucocutaneous manifestations, GI symptoms, pneumonitis, or fever at any dose of hydroxyurea |
| Essential thrombocytopenia  | 1. Platelet count >600 x 10⁹/L after 3 months of at least 2 g/d of hydroxyurea (2.5 g/d in patients with a body weight >80 kg), OR  
2. Platelet count >400 x 10⁹/L and WBC count <2.5 x 10⁹/L at any dose of hydroxyurea, OR  
3. Platelet count >400 x 10⁹/L and hemoglobin <10 g/dL at any dose of hydroxyurea, OR  
4. Presence of leg ulcers or other unacceptable mucocutaneous manifestations at any dose of hydroxyurea, OR  
5. Hydroxyurea-related fever |

*Organ extending by >10 cm from the costal margin.  
†Complete response is defined as hematocrit less than 45% without phlebotomy, platelet count ≤400 x 10⁹/L, WBC count ≤10 x 10⁹/L, and no disease-related symptoms. Partial response is defined as hematocrit less than 45% without phlebotomy or response in three or more of other criteria.

Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

Table of Contents

Overview ................................ ................................ .................... MS-2
Literature Search Criteria and Guidelines Update Methodology ................................ ................................ ..................... MS-2
Molecular Abnormalities in MPN .............................................. MS-3
Diagnostic Classification ...................................................... MS-5
Workup of Suspected MPN .................................................... MS-6
Assessment of Symptom Burden .......................................... MS-7
Management of Myelofibrosis .............................................. MS-8
Risk Stratification ................................................................. MS-8
Treatment Options ............................................................... MS-9
Treatment Recommendations Based on Symptom Assessment and Risk Stratification ................................ ................... MS-14
Management of Treatment-Related Anemia and Thrombocytopenia ................................................................. MS-15
Treatment Response Criteria ................................................ MS-15
Monitoring Response and Follow-up Therapy ........................ MS-16
Management of MF-Associated Anemia ................................. MS-17
Disease Progression to Advanced Phase or Transformation to Acute Myeloid Leukemia ................................................ MS-18
Supportive Care ................................................................. MS-20
Management of Polycythemia Vera and Essential Thrombocytemia ................................................................. MS-21
Risk Stratification ................................................................. MS-21
Treatment Options ............................................................... MS-22
Treatment Recommendations Based on Risk Stratification .... MS-25
Treatment Response Criteria ................................................ MS-26
Monitoring Response and Follow-up Therapy ........................ MS-27
Special Considerations in the Management of PV and ET ...... MS-28
Summary ............................................................................. MS-30
References ........................................................................... MS-31
Overview

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). The prevalence of MF, ET, and PV in the United States is estimated to be approximately 13,000, 134,000, and 148,000, respectively. In a more recent survey that assessed the incidence rates (IRs) of different subtypes of MPN in the United States (2001–2012), the IRs were highest for PV (IR = 10.9) and ET (IR = 9.6).

MPN are characterized by a complicated symptom profile and a risk of transformation to acute myeloid leukemia (AML) associated with a poor response to therapy and short survival. The profile varies within and between each MPN subtype but often includes constitutional symptoms, fatigue, pruritus, weight loss, symptoms from splenomegaly, and variable lab abnormalities, including erythrocytosis, thrombocytosis, and leukocytosis. A SEER-Medicare database analysis showed that patients with MPN have substantially inferior survival compared to matched controls, and the survival for patients with MF is worse than that of patients with ET or PV and significantly worse than matched controls.

The diagnosis and management of patients with MPN has evolved since the identification of “driver” mutations (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. However, certain aspects of clinical management regarding the diagnosis, assessment of symptom burden, and selection of appropriate symptom-directed therapies continue to present challenges for hematologists and oncologists.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the aim to provide recommendations for the management of MPN in adults. The NCCN Guidelines® for Myeloproliferative Neoplasms include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of MF, PV, and ET.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Myeloproliferative Neoplasms an electronic search of the PubMed database was performed to obtain key literature in Myeloproliferative Neoplasms published between April 2016 and March 2017 using the search terms: myeloproliferative neoplasms, myelofibrosis, polycythemia vera, and essential thrombocytemia. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 120 citations and their potential relevance was examined. The data from key PubMed articles selected by the panel for review during the Guidelines update meeting as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting...
abstracts). Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available on the NCCN webpage.

**Molecular Abnormalities in MPN**

*JAK2 V617F* mutations account for the majority of patients with PV (more than 90%) and 60% of patients with ET or MF.12-14 The V617F mutation occurs in exon 14, however, rare insertions and deletions have been found in exon 12. *JAK2 exon12* mutations have been described in 2% to 3% of patients with PV.15,16

Activating mutations in the thrombopoietin receptor gene (*MPL W515L/K*) are reported in approximately 5% to 8% of all patients with MF and 1% to 4% of all patients with ET.17-19

Mutations in exon 9 of the calreticulin gene (*CALR*) are reported in approximately 20% to 35% of all patients with ET and MF (accounting for about 60%–80% of patients with *JAK2/MPL*-negative ET and MF).20,21 *Type 1* (52 base pair deletions) and *Type 2* (5 base pair insertions) mutations are the most frequent variants. *CALR*-Type 1 mutations are more frequent in patients with MF and *CALR*-Type 2 mutations are preferentially associated with ET.22-24

Mutations in several other genes that are involved in signal transduction (*CBL, LNK/SH2B3*), chromatin modification (*TET2, EZH2, IDH1/2, ASXL1, DNM3TA*), RNA splicing (*SF3B1, SRSF2, U2AF1*), and tumor suppressor function (*TP53*) have also been reported in patients with MPN.25,26

**Myelofibrosis**

*CALR* mutation is associated with better overall survival (OS) than *JAK2 V617F* or *MPL W515* mutation and the survival advantage is significant in patients with type 1/type 1-like mutation.23,27-29 In a study of 617 patients with primary MF (PMF), the median OS was 17.7 years for those with *CALR* mutations versus 9.2 years, 9.1 years, and 3.2 years, respectively, for those with *JAK2 V617F* mutation, *MPL* mutation, and triple-negative patients, respectively.27 *CALR* mutations retained their prognostic significance for better OS compared to *JAK2 V617F* mutation (*P* = .19) or triple-negative status (*P* < .001) in a multivariate analysis corrected for age. The 10-year cumulative incidence of leukemic transformation was also lower (9.4%) for patients with *CALR* mutation compared to 19.4% for those with *JAK2 V617F* mutation, 16.9% for those with *MPL* mutation, and 34.4% for those who were triple negative. In the study that evaluated the prognostic impact of the two different types of *CALR* mutations in 396 patients with PMF, the median survival was significantly higher for patients with type 1/type 1-like mutation (26.4 years; *P* < .0001) versus 7.4 years and 7.2 years, respectively, for those with type 2/type 2-like mutation and *JAK2 V617F* mutation. The rate of leukemic transformation was also higher among patients with type 2/type 2-like mutation than those with type 1/type 1-like and *JAK2 V617F* mutation.29

*CALR* mutation is also associated with higher OS rates and lower rate of non-relapse mortality (NRM) following allogeneic HCT in patients with PMF as well as post-PV or post-ET MF.30 In a study of 133 patients who underwent allogeneic hematopoietic cell transplant (HCT) for PMF (n = 97) or post-ET/post-PV MF (n = 36), the 4-year OS rate was 82% for patients with *CALR* mutations compared to 56% for patients without *CALR* mutation (*CALR* wild-type). The NRM was also significantly lower in patients with *CALR* mutations compared with those who were *CALR* wild-type (4-year NRM 7% and 31%, respectively; *P* = .024).30
MPL mutations are associated with lower hemoglobin levels at diagnosis and increased risk of transfusion dependence in patients with MF. Approximately 10% of patients lack JAK2, CALR, or MPL mutations, referred to as “triple-negative” MPN that is associated with a worse prognosis in patients with MF.

ASXL1, EZH2, SRSF2, TP53, IDH1, or IDH2 mutations are considered as "high-molecular-risk" mutations, associated with significantly shorter OS and leukemia-free survival. ASXL1, EZH2, and SRSF2 mutations are predictive of OS, while ASXL1, SRSF2, and IDH1 or IDH2 are predictive of leukemic transformation in patients with PMF. TET2 or TP53 mutations have also been associated with a worsened overall prognosis and an increased rate of leukemic transformation. In a study that evaluated the prognostic significance of somatic mutations in 879 patients with PMF, the median survival was significantly shorter (81 vs. 148 months; P < .0001) in patients with at least one mutation in the prognostically significant genes (ASXL1, EZH2, SRSF2, IDH1, or IDH2) compared with those with no mutation in any of these genes.

However, only ASXL1 mutations retained prognostic significance after accounting for known prognostic factors. The results of a subsequent analysis that evaluated the additional prognostic value of the “number” of mutated genes in 797 patients with PMF confirmed that patients harboring ≥2 high-molecular-risk mutations had significantly reduced OS and leukemia-free survival compared not only in patients with no mutations but also in those presenting with only one high-molecular-risk mutation. The median OS was 2.6 years for patients with ≥2 high-molecular-risk mutations compared to 7.0 years and 11.1 years, respectively, for those with one high-molecular-risk mutation and no mutations. The corresponding leukemia-free survival was 6.6 years, 11.1 years, and 26.7 years, respectively.

An analysis that assessed the impact of both CALR and ASXL1 mutations on OS in 570 patients with PMF identified CALR(-)/ASXL1(+) mutational status as the most significant risk factor. The median OS was the longest in CALR(+)/ASXL1(-) patients (10.4 years) and shortest in CALR(-)/ASXL1(+) patients, and the OS was similar for CALR(+)/ASXL1(+) and CALR(-)/ASXL1(-) patients (5.8 years).

Polycythemia Vera and Essential Thrombocythemia

JAK2 exon 12-mutated PV is characterized by significantly higher hemoglobin level and lower platelet and leukocyte counts at diagnosis compared to JAK2-mutated PV. However, both JAK2 V617F and JAK2 exon 12 mutations are associated with similar rates of thrombosis, transformation to MF or leukemia, and death.

CALR-mutated ET is characterized by younger age, male sex, higher platelet count, lower hemoglobin, lower leukocyte count, and lower risk of thrombosis than JAK2- or MPL-mutated ET, whereas the presence of MPL mutations might be associated with a higher risk of fibrotic transformation. However, CALR mutations have no impact on OS or myelofibrotic or leukemic transformation. CALR mutation status also did not have a significant impact on the International Prognostic Score for ET (IPSET)-thrombosis prognostic score for predicting the risk of thrombosis.

Targeted sequencing has identified adverse variants/mutations in several other genes in PV and ET. In a cohort of 316 patients with PV (n = 133) or ET (n = 183), variants/mutations other than the 3 "driver" mutations were identified in 70 patients with PV (52.6%) and 96 patients with ET (52.5%). TET2 (22% in PV and 16% in ET) and ASXL1 (12% in PV and 11% in ET) mutations were the most frequent mutations. The presence of at least one of the 3 variants/mutations (ASXL1, SRSF2, and IDH2) was associated with inferior OS and MF-free survival but it
in patients with PV. In the multivariable analysis, \textit{ASXL1} and \textit{SRSF2} retained the prognostic significance for OS and \textit{ASXL1} was prognostic of MF-free survival. \textit{SH2B3}, \textit{IDH2}, \textit{U2AF1}, \textit{SF3B1}, \textit{EZH2}, and \textit{TP53} mutations were identified as significant risk factors for inferior OS, MF-free survival, and leukemia-free survival in patients with ET. Multivariable analysis confirmed the individual prognostic significance of \textit{U2AF1} mutation for OS and MF-free survival and \textit{TP53} mutation for leukemia-free survival.

### Diagnostic Classification

The WHO classification of myeloid neoplasm was first published in 2001 and was updated in 2008 to refine the diagnostic criteria for previously described neoplasms based on the new scientific and clinical information and to introduce newly recognized disease entities.\textsuperscript{46,47} It was revised again in 2016 to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the publication of the 2008 WHO classification.\textsuperscript{8,48}

The 2016 WHO diagnostic criteria now include molecular testing for \textit{JAK2}, \textit{CALR}, and \textit{MPL} mutations for PMF and ET and molecular testing for \textit{JAK2 V617F} or \textit{JAK2} exon 12 mutations for PV.\textsuperscript{8} In the absence of \textit{JAK2}, \textit{CALR}, and \textit{MPL} mutations, the presence of another clonal marker is included as one of the major diagnostic criteria for PMF.\textsuperscript{8} Additional mutations in \textit{ASXL1}, \textit{EZH2}, \textit{TET2}, \textit{IDH1}, \textit{IDH2}, \textit{SRSF2}, and \textit{SF3B1} genes are noted to be of use in determining the clonal nature of the disease.\textsuperscript{36,37}

MF can either present as a de novo disorder known as PMF or it can develop from the transformation of PV and ET (post-PV MF or post-ET MF).\textsuperscript{49} Prefibrotic/early-stage PMF is characterized by an increase in atypical megakaryocytes, reduced erythropoiesis, and increased age-matched bone marrow cellularity. However, overt bone marrow fibrosis might be absent in early-stage/prefibrotic PMF, leading to a diagnosis of ET.\textsuperscript{50} The revised 2016 WHO diagnostic criteria also include separate criteria for prefibrotic/early-stage PMF and overt fibrotic-stage PMF in order to differentiate true ET from prefibrotic/early PMF by the morphologic findings of the bone marrow biopsy, including the lack of reticulin fibrosis at onset.\textsuperscript{8}

In the International Working Group for MPN Research and Treatment (IWG-MRT) study that reevaluated 1104 patients with a diagnosis of ET, central pathology review revealed a diagnosis (as defined by the WHO criteria) of ET in 891 patients (81%) and early/prefibrotic PMF in 180 patients (16%). The remaining 33 patients (3%) were unevaluable.\textsuperscript{50} The frequency of grade 1 bone marrow fibrosis was greater in patients with early/prefibrotic PMF. In addition, leukocyte count, platelet count, serum lactate dehydrogenase (LDH) level, and the incidence of palpable splenomegaly were greater in patients with early/prefibrotic PMF, whereas hemoglobin level was greater in patients with ET. The long-term clinical outcomes were significantly worse for patients with early-stage/prefibrotic PMF. The 15-year rates of OS, leukemic transformation, and fibrotic progression were 59%, 11.7%, and 16.9%, respectively, for patients with ET. In multivariate analysis, bone marrow histopathology remained prognostically significant for survival ($P = .03$), leukemic transformation ($P = .007$), and overt fibrotic progression ($P = .019$). Therefore, accurate evaluation of bone marrow morphology is essential to distinguish early-stage/prefibrotic PMF from ET, especially since the long-term clinical outcomes are significantly better for patients with ET than for those with prefibrotic MF.

The diagnostic criteria for PV have also been refined to differentiate masked PV from ET (recognizing the utility of bone marrow biopsy in
patients with hemoglobin levels <18.5 g/dL in men and <16.5 g/dL in women). In an international study of 397 patients with JAK2 V617F or a JAK2 exon12 mutation and WHO-defined PV morphology, 257 patients were diagnosed with overt PV that met the full 2008 WHO diagnostic criteria for PV. The remaining 140 patients were classified as having masked PV with hemoglobin levels at diagnosis of <18.5 g/dL in men (range 16.0–18.4 g/dL) and <16.5 g/dL in women (range 15.0–16.4 g/dL) and frequent presence of subnormal erythropoietin (EPO) levels. In a multivariate analysis, the diagnosis of masked PV was an independent predictor of poor survival in patients age >65 years with a leukocyte count >10 x 10^9/L. In the absence of these risk factors, the outcome of patients with masked PV was similar to that of patients with overt PV, suggesting that a fraction of patients with lower hemoglobin levels should still be considered as overt PV. The results of a more recent study also showed that the OS, rates of thrombosis and major bleeding, and probability of transformation were similar among patients with masked and overt PV. Thus, the major diagnostic criteria for PV have been refined to include hemoglobin levels (>16.5 g/dL in men and >16.0 g/dL in women) or hematocrit >49% in men and >48% in women and a bone marrow biopsy to confirm the age-matched hypercellularity. However, bone marrow biopsy may not be required in patients with sustained absolute erythrocytosis (hemoglobin levels >18.5 g/dL in men [hematocrit, 55.5%] or >16.5 g/dL in women [hematocrit, 49.5%]) and JAK2 V617F or JAK2 exon 12 mutations and subnormal EPO levels.

The diagnosis of MPN should be based on the 2016 WHO diagnostic criteria and requires a combination of clinical, laboratory, cytogenetic, and molecular testing. The diagnosis of PMF requires meeting all 3 major criteria and at least one minor criterion as outlined in the revised 2016 WHO criteria. The diagnosis of PV requires meeting either all 3 major criteria or the first 2 major criteria and the minor criterion, whereas the diagnosis of ET requires meeting all 4 major criteria or the first 3 major criteria and the minor criterion as outlined in the revised 2016 WHO criteria. See 2016 WHO Diagnostic Criteria for PMF, PV, and ET in the algorithm for a list of major and minor criteria. The diagnosis of post-PV MF or post-ET MF is based on the 2008 IWG-MRT diagnostic criteria, requiring the documentation of a previous diagnosis of PV or ET as defined by the WHO criteria and the development of bone marrow fibrosis of grade 2–3 (or 3–4, depending on the scale) and at least 2 minor criteria.

**Workup of Suspected MPN**

Initial evaluation of patients with suspected MPN should include a history and physical exam, palpation of spleen, evaluation of thrombotic/hemorrhagic events, cardiovascular risk factors, and documentation of transfusion/medication history. Laboratory evaluations should include complete blood count (CBC), microscopic examination of the peripheral smear, comprehensive metabolic panel with serum uric acid, serum LDH, liver function tests, serum EPO level, and serum iron studies.

Fluorescence in situ hybridization (FISH) or a reverse transcriptase polymerase chain reaction (RT-PCR) on a peripheral blood specimen to detect BCR-ABL1 transcripts and exclude the diagnosis of CML is especially recommended for patients with left-shifted leukocytosis and/or thrombocytosis with basophilia. Molecular testing for JAK2 V617F mutations should be performed in all patients. If JAK2 V617F mutation testing is negative, molecular testing for MPL and CALR mutations should be performed for patients with MF and ET; molecular testing for the JAK2 exon12 mutation should be done for those with suspected PV and negative for the JAK2 V617F mutation.

Bone marrow aspirate and biopsy with trichrome and reticulin stain and bone marrow cytogenetics (karyotype, with or without FISH; blood, if
bone marrow is inaspirable) are necessary to accurately distinguish the bone marrow morphologic features between the disease subtypes (early or prefibrotic PMF, ET, and masked PV). Bone marrow histology shows hypercellularity and megakaryocytic proliferation. In the case of MF, bone marrow fibrosis is demonstrated on the reticulin stain and an additional trichrome stain is recommended to distinguish grade MF-1 from MF-2 or MF-3, as outlined in the 2016 WHO diagnostic criteria. Progression of PV or ET to MF can only be detected by performing a bone marrow biopsy; however, in patients with PV, bone marrow biopsy may not be required in patients with sustained absolute erythrocytosis (hemoglobin levels >18.5 g/dL in men [hematocrit, 55.5%] or >16.5 g/dL in women [hematocrit, 49.5%]), JAK2V617F or JAK2 exon12 mutations, and subnormal EPO level.

Human leukocyte antigen (HLA) typing should be performed for patients with MF for whom allogeneic HCT would be considered. Identification of high-molecular-risk mutations (ASXL1, EZH2, TET2, IDH1, IDH2, SRSF2, and TP53) may be helpful in decision-making regarding allogeneic HCT for patients with PMF. The prognostic significance of these high-molecular-risk mutations, perhaps with the exception of SRSF2 mutations, has not yet been established in patients with post-PV or post-ET MF. High-risk mutations in several other genes and variants of JAK2 and MPL mutations using next-generation sequencing (NGS) have also been identified in patients with PV and ET. NGS remains a research tool in many situations and the use of NGS in routine clinical practice is less well-established. However, it may be useful to establish clonality in selected circumstances (eg, “triple negative” MPN with non-mutated JAK2, MPL, and CALR).

MPN are associated with an increased risk of major bleeding and thrombosis/thromboembolism compared to the general population, and these events contribute considerably to morbidity and mortality in patients with MPN. Acquired von Willebrand disease (VWD) is associated with a variety of hematologic disorders, being particularly frequent in lymphoproliferative (48%) and myeloproliferative disorders (15%). Among MPN, the frequency of acquired VWD is more common among patients with ET (11%–17%) but can also be seen in patients with PV. Coagulation tests to evaluate for acquired VWD (plasma von Willebrand factor antigen measurement, von Willebrand ristocetin cofactor activity, von Willebrand multimer analysis, and Factor VIII level) and/or other coagulopathies (prothrombin time, partial thromboplastin time, and fibrinogen activity) are recommended for patients undergoing high-risk surgical procedures and those with elevated platelet count or unexplained bleeding.

**Assessment of Symptom Burden**

MPN are characterized by a complicated symptom profile resulting in reductions in quality of life, functional status, and activities of daily living. Constitutional symptoms (fever, night sweats, and weight loss) are more frequently reported in patients with MF compared to those with PV or ET. In a recent landmark survey that evaluated the symptom burden experienced by patients with MPN, disease-related symptoms were reported ≥1 year before diagnosis in 49% of patients with MF, 61% of patients with PV, and 58% of patients with ET. In an online survey of 1179 patients with MPN, fatigue was the most frequent symptom observed in 84% of patients with MF, 85% of patients with PV, and 72% of patients with ET. Additional symptoms included pruritus (52%), night sweats (49%), bone pain (44%), fever (14%), and weight loss (13%).

Various tools have been developed and validated in a large cohort of patients with MPN for the assessment of disease-related symptoms.
Myelofibrosis Symptom Assessment Form (MF-SAF) is a 20-item tool used for the assessment of MF-associated symptoms including fatigue, symptoms associated with splenomegaly (early satiety, abdominal pain or discomfort, inactivity, and cough), constitutional symptoms (night sweats, itching, bone pain, fever, and weight loss), and quality of life. MF-SAF was subsequently expanded to a 27-item tool, MPN Symptom Assessment Form (MPN-SAF), to include the assessment of additional symptoms that are relevant to ET and PV (insomnia, headaches, concentration, dizziness, vertigo, lightheadedness, numbness or tingling, depression, and sexual desire dysfunction). MPN-SAF was further simplified to a concise and abbreviated tool, MPN-SAF Total Symptom Score (MPN-SAF TSS; MPN 10), that is used for the assessment of the 10 most relevant symptoms in patients with MPN (fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) in both clinical practice and clinical trial settings. All 3 symptom assessment tools are coadministered with Brief Fatigue Inventory and the symptom severity is rated by patients on a scale of 1 to 10.

Assessment of symptoms at baseline and monitoring symptom status during the course of treatment is recommended for all patients. MPN-SAF is recommended for the assessment of symptom burden at baseline and MPN-SAF TSS is recommended for monitoring symptom status during the course of treatment. Management of Myelofibrosis

The treatment approach is currently identical for PMF and post-PV or post-ET MF. Referral to specialized centers with expertise in the management of MPN is strongly recommended for all patients diagnosed with MF.

Risk Stratification

Primary Myelofibrosis

The International Prognostic Scoring System (IPSS), dynamic International Prognostic Scoring System (DIPSS), and DIPSS-Plus are the 3 most common prognostic scoring systems used for the risk stratification of patients with MF. Other prognostic models incorporating mutational status (Mutation-Enhanced International Prognostic Scoring System [MIPSS] and Genetics-Based Prognostic Scoring System [GPSS]) have been developed to further refine the risk stratification. Further validation is essential before these models can be widely adopted for risk stratification of patients with MF.

IPSS should be used for the risk stratification at time of diagnosis. DIPSS-Plus is preferred for the risk stratification of MF during the course of treatment. DIPSS can be used if karyotyping is not available.

IPSS

Age >65 years, presence of constitutional symptoms, hemoglobin level <10 g/dL, leukocyte count > 25 x 10^9/L, and circulating blast cells 1% or greater at the time of diagnosis were identified as independent predictors of inferior survival. IPSS stratifies patients at the time of diagnosis into 4 different risk groups based on the presence of 0, 1, 2, and 3 or more adverse factors: low-risk, intermediate-1-risk (INT-1-risk), intermediate-2-risk (INT-2-risk), and high-risk with the median survival of 135 months, 95 months, 48 months, and 27 months, respectively (P < .001).

DIPSS

In a subsequent analysis that evaluated the impact of each adverse factor on survival during follow-up after treatment, all variables retained statistical significance. However, development of anemia over time
significantly affected survival (HR was approximately double than that of other adverse factors). Thus, a modified risk stratification system (DIPSS) was developed using the same prognostic variables as in IPSS (age >65 years, presence of constitutional symptoms, hemoglobin level <10 g/dL, leukocyte count >25 x 10^9/L, and circulating blast cells ≥1% at the time of diagnosis), but two points were assigned for hemoglobin <10 g/dL. The DIPSS can be applied at any point during the disease course to stratify patients into 4 different risk groups: low-risk (0 adverse points), INT-1-risk (1 or 2 points), INT-2-risk (3 or 4 points), and high-risk (5 or 6 points) with the median survival rates of not reached, 14.2 years, 4 years, and 1.5 years, respectively.

DIPSS-Plus
In subsequent reports, the need for red blood cell (RBC) transfusion, platelet count, and unfavorable karyotype have been identified as additional IPSS- and DIPSS-independent prognostic factors for inferior OS and leukemia-free survival in patients with PMF. The median survival of DIPSS low-risk patients with thrombocytopenia or unfavorable karyotype was 6.5 years compared to >15 years in the absence of these 2 additional risk factors. Similarly, the median survival was <1.5 years for DIPSS high-risk patients with one or more of these additional prognostic factors compared to approximately 3 years for those patients without these prognostic factors.

DIPSS was modified into DIPSS-Plus by the incorporation of platelet count <100 x 10^9/L, RBC transfusion need, and unfavorable karyotype (complex karyotype or one or two abnormalities that include trisomy 8, del 7/7q, i(17q), del5/5q, del12p, inv(3), or 11q23 rearrangement). DIPSS-Plus also stratifies patients into 4 risk groups based on the aforementioned 8 risk factors: low-risk (no risk factors), INT-1-risk (one risk factor), INT-2-risk (2 or 3 risk factors), and high-risk (4 or more risk factors) with respective median survival rates of 15.4, 6.5, 2.9, and 1.3 years.

Post-PV MF and Post-ET MF
The prognostic scoring systems described above have been studied and validated only in patients with PMF but have been clinically used for the risk stratification of patients with post-PV or post-ET MF. Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) is a novel prognostic model that stratifies patients with post-PV or post-ET MF into 4 risk groups, with distinct survival outcomes (low, INT-1, INT-2, and high risk) based on the hemoglobin level (<11 g/dL), circulating blasts (≥3%), CALR mutation status, platelet count (<150 x 10^9/L), and constitutional symptoms. The median survival was not reached at 9.3 years, 4.4 years, and 2 years, respectively. Further validation studies are necessary to confirm these findings.

Treatment Options
Interferons
Interferon alfa, peginterferon alfa-2a, and peginterferon alfa-2b have been evaluated in a small series of patients with MF.

In a prospective trial of 32 patients (12 patients with PMF, 7 patients with post-PV MF, 11 patients with post-ET MF, and 2 patients with PV), interferon alfa or peginterferon alfa resulted in an overall response rate (ORR) of 78% (9.4% CR, 37.5 % PR, 9.4% CI, and 21.8% of patients had SD). The corresponding response rates were 9.1%, 50%, 9.1%, and 18%, respectively, for patients with low-risk disease. Among the 15 patients with reduction in splenomegaly and evaluable bone marrow biopsies, reduction in bone marrow cellularity was observed in 7 patients and a significant improvement in megakaryocyte morphology, marrow architecture, and reductions of reticulin and collagen fibrosis were observed in 3 patients. Among the
22 patients with follow-up bone marrow biopsies, reduction in cellularity was observed in 12 patients after a median treatment duration of 2 years.\textsuperscript{75}

In another retrospective study of 62 patients with early MF treated with peginterferon alfa-2a, improvement in constitutional symptoms and complete resolution of thrombocytosis and leukocytosis were observed in 82\%, 83\%, and 69\% of patients, respectively, and a reduction of splenomegaly was seen in 46.5\% of patients.\textsuperscript{76}

**Ruxolitinib**

Ruxolitinib is a potent and selective JAK2 inhibitor approved for the treatment of intermediate-risk or high-risk MF. The safety and efficacy of ruxolitinib in patients with INT-2-risk or high-risk MF was evaluated in 2 phase III studies (COMFORT-I and COMFORT-II).\textsuperscript{77,78} The COMFORT studies did not include patients with INT-1-risk MF. The safety and efficacy of ruxolitinib in patients with INT-1-risk MF have been demonstrated in nonrandomized studies.\textsuperscript{79,80} The results from a retrospective analysis suggest that ruxolitinib may be an appropriate treatment option for symptomatic patients with low-risk MF.\textsuperscript{81} However, the efficacy of ruxolitinib in low-risk MF has not been evaluated in prospective clinical trials.

**Low-Risk MF**

In a retrospective study of 108 patients (25 patients with low-risk MF and 83 patients with INT-1-risk MF) treated with ruxolitinib, patients with low-risk MF experienced a substantial improvement in splenomegaly and constitutional symptoms.\textsuperscript{81} The proportion of patients with moderate to severe splenomegaly reduced from 64\% at the time of diagnosis to 16\% at the time of best response to ruxolitinib. The proportion with moderate or severe fatigue decreased from 90\% at the time of diagnosis to 37\% at the time of best response to ruxolitinib. Similar findings were observed for patients with INT-1-risk MF. The proportion of patients with moderate or severe splenomegaly decreased from 53\% at the time of diagnosis to 10\% at the time of best response to ruxolitinib, and the proportion of patients with moderate or severe fatigue decreased from 76\% at the time of diagnosis to 42\% at the time of best response to ruxolitinib.

**Intermediate-1-risk MF**

The ROBUST trial is an open-label phase II trial that evaluated the efficacy of ruxolitinib in patients with INT-1-risk MF (48 patients; 14 patients with INT-1-risk MF along with 13 patients with INT-2-risk MF and 21 patients had high-risk MF).\textsuperscript{79} The primary composite endpoint was the achievement of treatment success at 48 weeks after ruxolitinib therapy (≥50\% reduction in palpable spleen length and/or a ≥50\% decrease in MF-SAF). At 48 weeks, 46.7\% of the overall population achieved a reduction in mean palpable spleen length and the effect was seen across all risk groups (51.6\% of patients with INT-1-risk, 37\% of patients with INT-2-risk, and 48.6\% of patients with high-risk disease). A ≥50\% reduction in MF-SAF at 48 weeks was achieved in 20.8\% of patients in the overall population and across all risk groups (INT-1-risk, 21.4\%; INT-2-risk, 23.1\%; high-risk, 19.0\%). Improvements in MF-SAF were seen in 80.0\%, 72.7\%, and 72.2\% of patients with INT-1-risk, INT-2-risk, and high-risk disease, respectively.

**JUMP**

JUMP is an expanded-access phase III study designed to assess the safety and efficacy of ruxolitinib in patients with INT-2-risk or high-risk MF with or without splenomegaly or INT-1-risk MF with a palpable spleen (≥5 cm from the costal margin).\textsuperscript{80} Among 163 evaluable patients with INT-1-risk MF, at 24 and 48 weeks, 63.8\% and 60.5\% of patients achieved a ≥50\% reduction from baseline in palpable spleen length, respectively and an additional 19.6\% and 21.0\% of patients
had a 25% to <50% reduction in palpable spleen length, respectively. The median time to a ≥50% reduction in palpable spleen length was 4.7 weeks and the estimated probability of maintaining a response was 91% at 48 weeks and 88% at 60 weeks.

**Intermediate-2-risk/High-risk MF**

The results of COMFORT-I\(^\text{77,82,83}\) and COMFORT-II\(^\text{78,84,85}\) studies demonstrated that continuous ruxolitinib therapy was associated with significant clinical benefits in patients with MF in terms of reduction in spleen size, amelioration of disease-related symptoms, and improvement in quality-of-life and OS compared to either placebo or best available therapy for patients with INT-2-risk or high-risk MF (PMF, post-PV MF, or post-ET MF).

The COMFORT-I trial randomized 259 patients with INT-2-risk or high-risk MF to twice-daily ruxolitinib (n = 155) or placebo (n = 154).\(^\text{77}\) The starting dose of ruxolitinib was based on the baseline platelet count (15 mg twice daily for a platelet count of 100 x 10\(^9\)/L to 200 x 10\(^9\)/L and 20 mg twice daily for > 200 x 10\(^9\)/L) and patients with protocol-defined worsening splenomegaly were permitted to cross over from placebo to ruxolitinib. The primary endpoint (≥35% reduction in spleen volume as assessed by MRI at 24 weeks) was reached in 41.9% of patients in the ruxolitinib group as compared with 0.7% in the placebo group (\(P < .001\)). An improvement of ≥50% in the MF-SAFT at 24 weeks was seen in 45.9% of patients treated with ruxolitinib as compared with 0.7% in the placebo group (\(P < .001\)). An improvement of ≥50% in the MF-SAFT at 24 weeks was seen in 45.9% of patients treated with ruxolitinib as compared with 0.7% in the placebo group (\(P < .001\)). Long-term follow-up results confirmed the safety and durable efficacy of ruxolitinib for the treatment of patients with INT-2-risk or high-risk MF.\(^\text{82,83}\) The 5-year follow-up data showed that patients treated with ruxolitinib had prolonged median OS compared to placebo (not reached compared to 200 weeks for patients randomized to placebo; \(P = .25\)). Spleen response (≥35% reduction from baseline in spleen volume) was achieved in 59.4% of patients randomized to ruxolitinib and the median duration of spleen response was 168.3 weeks.\(^\text{83}\) At the time of this analysis, 111 patients from the placebo group had crossed over to ruxolitinib (median time to crossover was 39.9 weeks). The subgroup analyses showed that clinical benefit of ruxolitinib was seen across all patient subgroups including PMF, post-ET MF or post-PV MF, IPSS risk groups, and JAK mutation status (positive or negative), and there was also a nonsignificant trend toward longer OS for patients with IPSS INT-2-risk and high-risk MF treated with ruxolitinib. However, this study was not designed or powered to detect treatment efficacies between treatment arms within each subgroup.\(^\text{83,86}\)

In the COMFORT-II study, 219 patients with INT-2-risk or high-risk MF were randomized to ruxolitinib (n = 146) or best available therapy (n = 73).\(^\text{78}\) The primary endpoint was at least a 35% reduction in spleen volume as assessed with MRI or CT scan at 48 weeks. The starting dose of ruxolitinib was based on the baseline platelet count (15 mg twice daily if the platelet count was ≤200 x 10\(^9\)/L and 20 mg twice daily if the platelet count was >200 x 10\(^9\)/L). A total of 28% of the patients in the ruxolitinib arm had at least a 35% reduction in spleen volume at 48 weeks compared with 0% in the group receiving the best available therapy group (\(P < .0001\)). The median duration of response among patients treated with ruxolitinib was not reached, with 80% of patients still having a response at a median follow-up of 12 months.\(^\text{78}\) Patients receiving ruxolitinib had improved quality-of-life and role functioning as well as significant reductions in disease-related symptoms compared to those receiving best available therapy. Long-term follow-up results confirmed that ruxolitinib is associated with durable efficacy and survival benefit compared to best available therapy for patients with INT-2-risk or high-risk MF.\(^\text{84,85}\) At the time of 5-year final analysis, 53.4% of patients in the ruxolitinib arm achieved a ≥35% reduction in spleen size.
volume at any time on treatment, and spleen volume reductions of ≥35% were sustained with long-term therapy (median duration, 3.2 years).85 The median OS was not reached for patients in the ruxolitinib arm, and it was 4.1 years for those in the best available therapy arm.

The pooled analysis of COMFORT-I and COMFORT-II studies showed that patients with INT-2-risk or high-risk MF treated with ruxolitinib had prolonged OS, and the OS of patients with high-risk disease in the ruxolitinib group was similar to that of patients with INT-2-risk MF in the control group.87 Larger spleen size at baseline was associated with shortened survival, whereas any spleen volume reductions (>10% reduction in spleen size) and a palpable spleen length reduction of ≥25% correlated with longer survival.

Toxicity
Anemia and thrombocytopenia were the most common hematologic toxicities associated with ruxolitinib, consistent with its mechanism of action, and the incidences of grade 3/4 anemia or thrombocytopenia were higher during the first 8 to 12 weeks of treatment.77,78 In the COMFORT-I study, ecchymosis, dizziness, and headache were the most frequent nonhematologic toxicities associated with ruxolitinib, and diarrhea was the most frequent nonhematologic adverse event associated with ruxolitinib in the COMFORT-II study.77,78 In general, the incidences of nonhematologic toxicities decreased with long-term therapy.82,85

Ruxolitinib is associated with a potentially increased risk of opportunistic infections.88,89 In particular, tuberculosis, progressive multifocal leukoencephalopathy, reactivation of hepatitis B virus, and herpes simplex virus have been reported in patients treated with ruxolitinib.83,90-94 Patients should be monitored for signs and symptoms of infections. Serious infections should be resolved prior to initiation of ruxolitinib.

Ruxolitinib is contraindicated in patients with evidence of active or latent tuberculosis. Viral reactivations should be treated and monitored according to clinical guidelines.

Impact of Mutational Status and Response to Ruxolitinib
In the COMFORT-II study, ruxolitinib was associated with clinical efficacy and survival improvement across different molecular subsets of patients with MF.95 Higher molecular risk mutations (ASXL1, EZH2, SRSF2, IDH1, or IDH2) were identified in 32.5%, 7.2%, 4.4%, 3.0%, 0.7%, and 0.0% of patients, respectively, and these frequencies were comparable in ruxolitinib and best available therapy arms. Responses in splenomegaly (>35% spleen volume reduction), symptomatic improvement, and the risk of ruxolitinib-associated anemia and thrombocytopenia were observed at similar frequencies across different mutation profiles. Ruxolitinib improved survival and reduced the risk of death in patients harboring higher molecular risk mutations (ASXL1, EZH2, SRSF2, IDH1, or IDH2) with a hazard ratio of 0.57.95

The results of another analysis of 95 patients with MF treated with ruxolitinib in a single institution also showed that ASXL1, EZH2, and IDH1/2 mutations are associated with poor outcomes and patients with ≥1 mutations in ASXL1, EZH2, or IDH1/2 had shorter time to treatment discontinuation and OS.96 However, in contrast to the findings of the COMFORT-II study, patients with ≥1 mutations in ASXL1, EZH2, or IDH1/2 were significantly less likely to have a spleen response. Patients with ≥3 mutations had the worst outcomes, suggesting that multigene profiling may be useful for treatment planning in patients with MF.

Allogeneic Hematopoietic Cell Transplant
Allogeneic HCT is the only treatment that is potentially curative resulting in long-term remissions for patients with MF. However, the use of myeloablative conditioning is associated with higher rates or
treatment-related NRM. The estimated OS rates and NRM rates at 3 to 5 years range from 30% to 61% and 24% to 43%, respectively. In a retrospective registry analysis of 289 patients with MF, allogeneic HCT resulted in long-term OS in about a third of patients, but the probability of long-term survival and NRM was dependent on the source of stem cells. The 5-year post-transplant OS rates were 37%, 40%, and 30%, respectively, for HLA-matched sibling donor transplant, other related donor transplant, and unrelated donor (URD) transplant, respectively. The corresponding 5-year disease-free survival rates were 33%, 22%, and 27%, respectively. The NRM rate at 5 years was higher for URD transplant (50% compared to 35% and 38% for HLA-matched sibling donor transplant and other related donor transplant, respectively).

The use of reduced-intensity conditioning (RIC) has lowered the rates of NRM but it is also associated with a higher risk of relapse compared to myeloablative conditioning. In a prospective, multicenter study that evaluated the allogeneic HCT with RIC in 103 patients with MF, the cumulative incidence of NRM at 1 year was 16% and the cumulative incidence of relapse at 3 years was 22%. The estimated 5-year event-free survival and OS rates were 51% and 67%, respectively. The NRM was significantly lower for patients with a completely matched donor (12% vs. 38%; \( P = .003 \)). Other large retrospective registry analyses have also reported similar outcomes. In the CIBMTR analysis that included 233 patients who underwent allogeneic HCT using RIC for PMF, the probabilities of OS and progression-free survival (PFS) at 5 years were 47% and 27%, respectively. The cumulative incidence of NRM and relapse/progression at 5 years were 24% and 48%, respectively. In the EBMTR analysis that included 193 patients who underwent transplantation for post-PV or post-ET MF, the 3-year OS rate, incidence of relapse, and NRM were 55%, 32%, and 28%, respectively.

Age (>55 years) and donor type (HLA-identical sibling donor transplant vs. HLA-well-matched URD transplant or partially/mismatched URD transplant) have been the most important prognostic factors of OS and NRM. Among patients who underwent allogeneic HCT with RIC for PMF, the 5-year survival rates following HLA-identical sibling donor transplant, HLA-well-matched URD transplant, and partially/mismatched URD transplant were 56%, 48%, and 34%, respectively (\( P = .002 \)) and the relative risk of NRM was also the lowest for HLA-identical sibling donor transplant (1%) compared to 3.02% and 9.37% for HLA-well-matched URD transplant and partially/mismatched URD transplant, respectively. In patients who underwent allogeneic HCT with RIC for post-PV MF or post-ET MF, the overall 3-year cumulative incidence of NRM was significantly higher in patients >55 years (35% vs. 20% for younger patients; \( P = .032 \)) and in those who underwent URD transplant (34% vs. 18% for those who had a related donor transplant; \( P = .034 \)).

DIPSS risk score has been shown to predict outcome after transplant. In the aforementioned CIBMTR analysis, there was a trend towards lower mortality rates in patients with low-risk/INT-1-risk disease and higher NRM in patients with INT-2-risk/high-risk disease. In another retrospective analysis of 170 patients with MF who received HCT, DIPSS risk score significantly correlated with mortality risk and NRM (hazard ratio for post-transplant mortality was 4.11 for high-risk disease compared to 3.15, 1.97, and 1, respectively, for INT-2-risk, INT-1-risk, and low-risk disease; the corresponding hazard ratios for NRM were 3.41, 3.19, 1.41, and 1, respectively). The association of DIPSS risk score with relapse was not significant,
although patients with higher-risk disease experienced more relapses than those with lower-risk disease.

DIPSS risk scores prior to HCT have also been shown to correlate with OS following allogeneic HCT. However, in one retrospective analysis, the differences in OS between patients with INT-1-risk and INT-2-risk disease were not significantly different. In a multivariate analysis, only JAK2 wild-type, age ≥57 years, and the presence of constitutional symptoms were independent predictors of OS. The 5-year OS rates were 90%, 74%, and 50% for the presence of 0, 1, and 2 risk factors. In another retrospective analysis that evaluated the impact of allogeneic HCT on survival in patients <65 years of age at the time of diagnosis of PMF (n = 438; 190 patients received allogeneic HCT and 248 patients received conventional therapy), the relative risk of death after allogeneic HCT was 5.6 for patients with DIPSS low-risk disease, 1.6 for INT-1-risk disease, 0.55 for INT-2-risk, and 0.37 for high-risk disease.

These findings suggest that outcomes following allogeneic HCT are better for patients with low-risk or INT-1-risk MF. However, it is also associated with high transplant-related morbidity and mortality in these patients. Allogeneic HCT is included as an option for patients with INT-2-risk/high-risk PMF.

Treatment Recommendations Based on Symptom Assessment and Risk Stratification

The selection of appropriate treatment should be based on the risk score and the presence of symptoms. Enrollment in clinical trial is recommended for all patients with the aim of reducing bone marrow fibrosis, improving cytopenias and symptom burden, restoring transfusion-independence, and preventing/delaying progression to AML.

Low-risk or INT-1-risk MF

Asymptomatic patients with low-risk or INT-1-risk MF should be observed. Ruxolitinib or interferons (interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b) are included as options for symptomatic patients. Hydroxyurea has been shown to be an effective treatment option for the hyperproliferative manifestations of MF (thrombocytosis or leukocytosis). In a small study of 40 patients with symptomatic MF (constitutional symptoms, splenomegaly, thrombocytosis, leukocytosis, pruritus, and bone pain), treatment with hydroxyurea (500 mg/d, subsequently adjusted to the individual efficacy and tolerability) resulted in clinical improvement (CI) in 40% of patients. Anemia induced by hydroxyurea was manageable with concomitant treatment. The panel has included hydroxyurea as an option for low-risk MF, if the use of cytoreductive therapy would be symptomatically beneficial in selected patients with high platelet counts.

Allogeneic HCT is included as an option for patients with INT-1-risk MF. Evaluation for allogeneic HCT is recommended for patients with low platelet counts and identification of potentially high-molecular-risk mutations may be helpful in the decision-making regarding allogeneic HCT. Although the outcomes following allogeneic HCT is better for patients with low-risk or INT-1-risk MF, due to the high transplanted-related morbidity and mortality, treatment decisions regarding allogeneic HCT should be individualized for patients with INT-1-risk MF.

INT-2-risk or High-risk MF

Evaluation for allogeneic HCT is recommended for all patients with INT-2-risk and high-risk MF. The selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of
Patients may be taken immediately to allogeneic HCT or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to allogeneic HCT. Identification of high-molecular-risk mutations may be helpful in decision-making regarding allogeneic HCT.36,37

Allogeneic HCT is recommended for patients with INT-2-risk or high-risk MF if they are candidates for transplant.107 In patients who are not candidates for transplant, treatment options are based on the platelet count. Ruxolitinib77,78,82-84 or clinical trial are included as options for patients with platelet count >50K. Although symptomatically guided treatment is a reasonable option for patients with platelet count ≤50K, at the present time, there are no effective treatment options for this group of patients since the majority of clinical trials evaluating treatment options for MF have excluded this group of patients. The use of ruxolitinib at a lower dose (5 mg twice daily) has been shown to be effective resulting in reductions in spleen volume and improvement in total symptom score even in patients with low platelet counts at baseline (50–100 x 10^9/L).111 While ruxolitinib could be considered in symptomatic patients with platelet count ≤50K, it is not FDA approved for this indication. Pacritinib (another JAK2 inhibitor) has also demonstrated significant activity resulting in ≥35% spleen volume reductions and symptom improvement, even in patients with severe baseline cytopenias.112 Pacritinib could be an appropriate treatment option for patients with low platelet counts; however, it is not yet FDA approved. Therefore, enrollment in an appropriate clinical trial should be considered for patients with platelet count ≤50K.

Management of Treatment-Related Anemia and Thrombocytopenia

In COMFORT-I and COMFORT-II studies, anemia and thrombocytopenia were managed with dose modifications and RBC transfusions.77,78 Patients enrolled in the COMFORT trials were required to have a baseline platelet count of ≥100 x 10^9/L, and the initial starting dose of ruxolitinib was dependent on the patient’s baseline platelet counts.77,78 Preliminary results of the phase II study suggest that a lower initial dose of ruxolitinib (5 mg twice daily) with escalation to 10 mg BID may be appropriate in patients with baseline platelet counts of 50–100 x 10^9/L.111

The guidelines recommend that the initial dosing of ruxolitinib should be based on the patient’s baseline platelet counts (as described in the full prescribing information). However, certain clinical situations may support initiation of ruxolitinib at a lower dose (5 mg twice daily) with subsequent dose modifications based on CBC, which must be performed before initiating ruxolitinib and monitored every 2 to 4 weeks until the dose is stabilized, and then as clinically indicated.111,113 Special Considerations for the Use of Ruxolitinib in the algorithm for dose modifications for the management of hematologic toxicities.

Treatment Response Criteria

In 2006, the IWG-MRT first published the response criteria for MF and the responses were categorized as complete response (CR), partial response (PR), CI, progressive disease (PD), stable disease (SD), and relapse.114 In 2013, these response criteria were revised by IWG-MRT and European LeukemiaNet (ELN) to include MPN-SAF TSS as a quantifiable tool to assess changes in disease-related symptoms and stricter definitions of RBC transfusion dependency and independency.115 These response criteria were developed mainly for use in clinical trials.

In addition to CR, PR, and CI, 3 other response categories (anemia response, spleen response, and symptoms response) have been included in the revised 2013 IWG-MRT and ELN response criteria to...
quantify treatment-induced improvements in symptom burden, particularly anemia, splenomegaly, and constitutional symptoms. The revised response criteria recommend that symptoms should be evaluated by the MPN-SAF TSS and symptom response requires ≥50% reduction in the TSS. The revised 2013 IWG-MRT and ELN response criteria also require that a ≥35% reduction in spleen volume should be confirmed by MRI or CT scan. In addition, ≥35% reduction in spleen volume by MRI or CT scan constitutes a spleen response regardless of that reported by physical examination. Additional criteria are also included for PD, SD, and relapse.

Morphologic response in bone marrow is required for CR. The criteria for PR require morphologic response in the peripheral blood (but not necessarily in the bone marrow). Patients meeting criteria for CR with inadequate blood count recovery are also included in the PR category to capture those patients who have achieved CR with persistent drug-induced cytopenia despite a morphologically normal bone marrow. The revised response criteria also include response categories for cytogenetic and molecular response. However, these are not required for CR assignment.

Monitoring Response and Follow-up Therapy

The goal of treatment is to reduce symptom burden and minimize the risk of leukemic transformation. Changes in symptom status could be a sign of disease progression. Therefore, change in symptom status should prompt evaluation of treatment efficacy and/or disease status. Evaluation of treatment efficacy should include CBC to assess normalization of blood counts, monitoring symptom status using MPN-SAF TSS, and monitoring spleen size either by palpation or imaging. The guidelines recommend monitoring response (anemia response, spleen response, and symptom response), signs, and symptoms of disease progression every 3 to 6 months during the course of treatment. Bone marrow aspirate and biopsy should be performed as clinically indicated (if supported by increased symptoms and signs of progression). Additional molecular monitoring is recommended for patients with INT-1-risk or INT-2-risk/high-risk disease since the identification of high-molecular risk mutations may be helpful in the decision-making regarding allogeneic HCT.

Continuation of prior treatment is recommended for patients achieving response to initial treatment. In the COMFORT-I study, the majority of patients (91%) treated with ruxolitinib experienced significant improvements in individual MF-related symptoms (≥50% improvement in total symptom score as assessed by MF-SAF) and quality of life; most importantly, patients with a lesser degree of symptom improvement (<50% improvement in total symptom score) also achieved improvements over placebo on these measures and other patient-reported outcomes. The panel acknowledges that clinical benefit may not reach the threshold of the 2013 IWG-ELN Response Criteria (ie, symptom response requires ≥50% reduction in the MPN-SAF TSS) in patients receiving treatment with ruxolitinib. Continuation of ruxolitinib is recommended based on the discretion of the clinician, since a symptom response of <50% may be clinically meaningful and justify the continued use of ruxolitinib.

Ruxolitinib should be discontinued if there is no response or improvement of symptoms after 6 months. However, disease-related symptoms may return to pretreatment levels over a period of approximately one week following discontinuation or interruption of ruxolitinib. Gradual tapering the dose of ruxolitinib should be considered, when discontinuing or interrupting ruxolitinib for reasons
other than thrombocytopenia or neutropenia. See the section Special Considerations for the use of Ruxolitinib in the algorithm.

**JAK2V617F Allele Burden**

Long-term ruxolitinib therapy is associated with reductions in \textit{JAK2V617F} allele burden.\textsuperscript{85,117} In the COMFORT-I study, >50% reductions in \textit{JAK2V617F} allele burden was observed in 12% of patients (28 patients); 20 of these patients met the criteria for partial molecular response (PMR) and 6 patients had \textit{JAK2V617F} allele burden values below quantifiable limit, meeting the criteria for complete molecular response (CMR).\textsuperscript{117} The median times to PMR and CMR were 22.2 and 27.5 months, respectively. \textit{JAK2V617F} allele burden reductions also correlated with spleen volume reductions. Achievement of \textit{JAK2V617F} negativity or \textit{JAK2V617F} allele burden reduction after allogeneic HCT has also been associated with a decreased incidence of relapse.\textsuperscript{118,119}

However, at the present time, the utility of \textit{JAK2V617F} allele burden reduction as a predictor of treatment efficacy is not well established. In the 2013 IWG-MRT and ELN response criteria, cytogenetic and molecular responses are not required for CR assignment.\textsuperscript{115} Therefore, measurement of the \textit{JAK2V617F} allele burden is not currently recommended for use in routine clinical practice to guide treatment decisions.

**Management of MF-Associated Anemia**

Anemia is considered a negative prognostic risk factor for survival in patients with MF.\textsuperscript{65} Symptomatic anemia is observed in more than 50% of patients at the time of diagnosis.\textsuperscript{120} It is essential to rule out and treat (if necessary) the most common causes of anemia (eg, bleeding; hemolysis; deficiency of iron, vitamin B12, and folic acid) before considering other treatment options. Enrollment in a clinical trial should be considered for all patients with MF-associated anemia. Leuco-reduced RBC transfusion support is recommended for symptomatic anemia. Additional treatment options for the management of MF-associated anemia are based on the serum EPO levels as described below.

**Serum EPO <500 mU/mL**

Erythropoietin-stimulating agents (ESAs; erythropoietin or darbepoetin alfa) are recommended for the treatment of anemia for patients with serum EPO levels <500 mU/mL. The use of recombinant human erythropoietin or darbepoetin alfa has resulted in anemia responses (transfusion independence with normal hemoglobin levels, sustained increase in hemoglobin levels [\textgreater{}2 g/dL] within 12 weeks, or \textgreater{}50% reduction in transfusion requirements within 12 weeks) in 45% to 60% of patients with MF.\textsuperscript{121-123} Lower serum EPO levels (<125 mU/mL), smaller spleen size and low RBC transfusion requirements have been associated with favorable responses. In the COMFORT-II study, anemia was managed with packed RBC transfusions and only a small number of patients (13 out of 166 patients) received both ruxolitinib and an ESA. The concomitant use of an ESA with ruxolitinib was well tolerated and did not affect the efficacy of ruxolitinib.\textsuperscript{124} Additional studies are warranted to evaluate the efficacy of ESAs for the management of anemia in patients receiving ruxolitinib. ESAs are not effective for the management of transfusion-dependent anemia.\textsuperscript{125}

Continuation of treatment with ESA is recommended in patients achieving anemia response; those with no response or loss of response should be managed with androgens or immunomodulatory agents as described below.
**Serum EPO ≥500 mU/mL**

Danazol (or alternative androgens) or immunomodulatory agents (lenalidomide or thalidomide or pomalidomide) with or without prednisone are recommended for patients with serum EPO levels >500 mU/mL.

In a study of 50 patients with MF and anemia, danazol therapy resulted in an anemia response in 30% of patients and responses are less frequent in patients with transfusion dependency (18.5% compared to 43.5% in patients without transfusion requirements).\(^\text{126}\) Prostate cancer screening and monitoring of liver function tests are recommended for patients receiving danazol for the management of MF-associated anemia.

Thalidomide (in escalating daily doses of 100 mg to 800 mg) has demonstrated very minimal efficacy resulting in anemia response rates of 0% to 29% and is also poorly tolerated.\(^\text{127-133}\) Lower dose of thalidomide (50 mg/d) when used in combination with prednisone is better tolerated, leading to improved anemia response rates (62%) compared to high-dose thalidomide monotherapy in the management of MF-associated symptomatic anemia (hemoglobin level <10 g/dL or symptomatic splenomegaly).\(^\text{134}\) Lenalidomide, alone or in combination with prednisone, has also demonstrated modest efficacy in the management of MF-associated anemia, resulting in response rates of 19% to 32% with myelosuppression being the most common ≥ grade 3 hematologic toxicity.\(^\text{135-138}\)

In an analysis that reassessed the efficacy of thalidomide and lenalidomide in 125 patients with MF treated in 3 consecutive phase 2 trials, the combination of lenalidomide and prednisone was more effective and safer than single-agent thalidomide or lenalidomide.\(^\text{139}\) After a median follow-up of 42 months, the ORR was 38% for the combination of lenalidomide and prednisone compared to 34% and 16%, respectively, for lenalidomide and thalidomide. There was also a trend for a higher efficacy in patients receiving lenalidomide-based therapy (\(P = .06\)), and in a multivariate analysis the lenalidomide-based regimen was the only factor independently associated with a higher response rate. The presence of del(5q) is associated with better response rates with lenalidomide.\(^\text{140}\)

Pomalidomide has also been evaluated as a treatment option for MF-associated anemia.\(^\text{141,142}\) In one phase II study, pomalidomide (with or without prednisone) resulted in similar response rates (39%) in patients with MF and anemia and/or thrombocytopenia and/or neutropenia, with a median response duration of 13.0 months.\(^\text{141}\) However, in another randomized study that evaluated pomalidomide in patients with MF and RBC-transfusion dependence, the RBC-transfusion-independence response rates were similar for patients treated with pomalidomide and placebo.\(^\text{142}\) The panel has included pomalidomide (with or without prednisone) as a category 3 recommendation for the management of MF-associated anemia.

Continuation of prior treatment is recommended in patients achieving anemia response, and those with no response or loss of response should be given another trial of alternative androgen or immunomodulating agent that has not been used before.

**Disease Progression to Advanced Phase or Transformation to Acute Myeloid Leukemia**

MF in accelerated phase (MF-AP) is characterized by the presence of ≥10% blasts in the peripheral blood or bone marrow, platelets <50 × 10⁹/L, and chromosome 17 aberrations.\(^\text{143}\) In a cohort of 293 patients who presented with chronic phase MF, development of AP features during follow-up was associated with short median survival times (12
months, 15 months, and 6 months for ≥10% blasts, platelets <50 x 10^9/L, and chromosome 17 aberrations, respectively.\textsuperscript{143}

MF in blast phase or transformation to AML (MF-BP/AML) is defined by the presence of ≥20% myeloid blasts in either the bone marrow or peripheral blood. The incidence of transformation to AML is significantly higher for patients with MF (1.09\% compared to 0.38\% and 0.37\%, respectively, for PV and ET).\textsuperscript{144} However, the risk of transformation is very low in patients who remain in chronic phase MF (3\% risk at 10 years).\textsuperscript{143} In some studies, treatment with hydroxyurea has been associated with increased risk of transformation to AML.\textsuperscript{145,146} These findings were not confirmed in subsequent reports.\textsuperscript{147-149} The results of a large cohort analysis (n = 11,039; 162 patients with transformation to AML/MDS) showed that the use of alkylating agents or a combination of ≥2 cytoreductive treatments (but not treatment with hydroxyurea alone) was associated with an increased risk of transformation to AML.\textsuperscript{147} In another large analysis of 649 patients with PMF, post-PV MF, or post-ET MF, bone marrow blasts ≥10\% and high-risk karyotypes were identified as independent poor prognostic factors for the transformation to AML.\textsuperscript{149} Hydroxyurea, however, was not an independent risk factor for transformation to AML although it was found to be associated with shorter OS.

Bone marrow aspirate and biopsy with trichrome and reticulin stain and bone marrow cytogenetics (karyotype, with or without FISH), flow cytometry, and molecular testing for AML-associated mutations are recommended as part of initial workup. Mutations in several genes (ASXL1, TET2, TP53, SRSF2, and IDH1 or IDH2) and other chromosomal abnormalities (eg, aberrations in chromosomes 1q and 9p) have been associated with transformation to AML.\textsuperscript{26,36,38,150}

**Treatment Options**
Transformation to AML is associated with poor prognosis and poor response to standard treatment options.\textsuperscript{151-153} In a retrospective analysis of 91 patients with MF that had transformed to AML, the median OS after transformation to AML was 2.6 months. Among patients who were treated with AML-type induction chemotherapy, reversal to chronic phase without an increase in the blast percentage occurred in 41\% of patients.\textsuperscript{151} However, it was also associated with a treatment-related mortality (TRM) rate of 33\%. The median OS was 3.9 months, which was comparable to that observed in patients treated with supportive care or low-intensity chemotherapy (2.0 months and 2.9 months, respectively).

Hypomethylating agents (azacytidine or decitabine) have been evaluated in few small studies as a treatment option for MPN that has transformed to AML.\textsuperscript{154-156} In a small series of 11 patients with MF-BP/AML, decitabine was associated with improved survival in patients who were not eligible for allogeneic HCT.\textsuperscript{154} At a median follow-up of 9 months, 67\% of the patients treated with decitabine were alive. In another series of 54 patients with MPN-BP/AML, first-line therapy with azacytidine resulted in an ORR of 52\% (24\% CR, 11\% PR, 8\% bone marrow CR or CR with incomplete recovery of cytopenias, and 9\% hematologic improvement).\textsuperscript{155} The median duration of response and the median OS were 9 months and 11 months, respectively. In a retrospective analysis of 21 patients with MPN-BP/AML and 13 patients with MPN-AP treated with decitabine, the ORRs were 62\% (8 out of 13 patients) and 29\% (6 out of 21 patients), respectively, for patients with MPN-AP and MPN-BP/AML.\textsuperscript{156} The median OS was significantly higher in patients with disease that responded to decitabine (11.8 months vs. 4.7 months, respectively, for
patients with MPN-AP; 10.5 months vs. 4 months, respectively, for patients with MPN-BP/AML).

Allogeneic HCT remains the only curative option resulting in long-term disease control in selected transplant-eligible patients who achieve a CR to induction chemotherapy. In one retrospective analysis of 75 patients with MPN-BP/AML, patients who were treated with curative intent (induction chemotherapy with or without allogeneic HCT) had significantly improved survival compared with those treated with non-curative intent (non-intensive chemotherapy or supportive care). The 2-year OS rates were 25.6% and 3.1%, respectively, and the median survival was 9.4 months and 2.3 months, respectively ($P < .0001$). Among patients treated with curative intent, the ORR to induction chemotherapy was 46% and reversal to chronic phase was observed in 31% of patients, with 17 patients undergoing allogeneic HCT. The OS rate was significantly higher for patients who underwent allogeneic HCT following induction chemotherapy (2-year OS rate was 47% compared with 15% for those who did not undergo allogeneic HCT; $P = .03$). In another retrospective analysis of 46 patients who received allogeneic HCT for MF-BP/AML, the 3-year PFS and OS rates following transplant were 26% and 33%, respectively. The response status prior to transplant (CR vs. no CR) was a significant predictor of OS (69% for CR vs. 22% for no CR; $P = .008$) and PFS (55% and 19%, respectively; $P = .02$). The cumulative incidence of TRM was 28% at 1 year and the absence of CR before allogeneic HCT was also associated with significantly increased TRM (35% vs. 0%, $P = .053$).

**Treatment Recommendations Based on Eligibility for Transplant**

The selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and the availability of caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

Disease control/reduction in blast counts with hypomethylating agents (azacytidine or decitabine) or intensive AML-type induction chemotherapy followed by allogeneic HCT is recommended for patients who are candidates for transplant. Enrollment in a clinical trial or treatment with hypomethylating agents (azacytidine or decitabine) or low intensity AML-type induction chemotherapy is recommended for those who are not candidates for transplant.

The results of a recent retrospective analysis suggest that prior exposure to ruxolitinib did not adversely affect post-transplantation outcomes and that ruxolitinib should be continued near to the start of conditioning therapy. The guidelines recommend continuation of ruxolitinib for all patients for the improvement of splenomegaly and other disease-related symptoms.

**Supportive Care**

Supportive care for disease-related symptoms should be an integral part of clinical management during the course of treatment. This should include assessment and monitoring symptom status, counseling for the identification, and assessment and management of cardiovascular risk factors (eg, smoking, diet, exercise, thrombotic and hemorrhagic risk factors).

Transfusion support should include platelet transfusions for thrombocytopenic bleeding or a platelet count <10,000 m³ and RBC transfusions for symptomatic anemia. The use of leukocyte-reduced blood products is recommended in transplant candidates to prevent HLA alloimmunization and reduce the risk of cytomegalovirus transmission. Antifibrinolytic agents should be considered for bleeding...
that is refractory to transfusions. Iron chelation could be considered for patients that have received >20 transfusions and/or ferritin >2500 ng/mL in patients with low-risk or INT-1-risk disease.\textsuperscript{161} However, the role of iron chelation remains unclear. Cytoreductive therapy (eg, hydroxyurea) is recommended for thrombocytosis or leukocytosis.

Serious bacterial, fungal, and viral infections have been reported in patients receiving ruxolitinib. Patients should be monitored for signs and symptoms of infections. Serious infections should be resolved prior to initiation of ruxolitinib. Antibiotic prophylaxis and vaccinations for recurrent infections are recommended as outlined in the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections. In splenectomized patients, antibiotic prophylaxis should be given per IDSA Guidelines. Growth factor support should be considered for recurrent infections with neutropenia. Cytoreductive therapy with hydroxyurea could be considered for the management of hyperproliferative manifestations of PMF (thrombocytosis or leukocytosis).\textsuperscript{110}

Risk Stratification

Retrospective studies have shown that leukocytosis at diagnosis is associated with higher risk of thrombosis and major hemorrhage in patients with PV and ET.\textsuperscript{162-166} Data from some studies suggest that the prognostic significance of leukocytosis for the risk of recurrent thrombosis may be significant only in patients <60 years of age,\textsuperscript{167,168} and other studies have reported that leukocytosis at diagnosis is not associated with the risk of subsequent thrombosis.\textsuperscript{169} Thrombocytosis (platelet count >1000 x 10^9/L) has been associated with an immediate risk of major hemorrhage but not with the risk of thrombosis in patients with ET.\textsuperscript{166} In fact, some studies have reported that elevated platelet counts at diagnosis (>1000 x 10^9/L) is associated with significantly lower rate of thrombosis and this association was significant even in patients with JAK2-mutated ET.\textsuperscript{164,165} The potential benefit of initiation of cytoreductive therapy based on elevated blood counts (leukocytosis or thrombocytosis) at the time of diagnosis has not been evaluated in prospective studies.

Polycythemia Vera

Advanced age (ie, > 60 years) and history of thrombosis are the most consistent risk factors associated with the risk of thrombosis.\textsuperscript{170} In a cohort of 1638 patients with PV who were screened for inclusion in the ECLAP trial, age >65 years and a previous history of thrombosis were the two most important prognostic factors associated with an increasing risk of cardiovascular events resulting in the identification of 2 different risk groups: low-risk (age <60 years and no prior history of thrombosis) and high-risk (age >60 years and/or prior history of thrombosis).

In another retrospective study of 1545 patients with PV, age ≥67 years, leukocyte count ≥15 x 10^9/L and venous thrombosis were identified as independent risk factors for leukemia-free survival.\textsuperscript{171} A prognostic model incorporating leukocytosis at the time of diagnosis in addition to
age has been developed to stratify patients into 3 risk groups with different survival outcomes. However, this model has not been validated in prospective clinical trials.

**Essential Thrombocythemia**

In an analysis of 867 patients with ET, age ≥60 years or older, leukocyte count ≥11 x 10^9/L and prior thrombosis were significantly associated with inferior survival. Based on these findings, IPSET was developed to stratify patients at the time of diagnosis into 3 risk categories: low-risk, intermediate-risk, and high-risk. The median survival was not reached for the low-risk group and the median survival was 24.5 years and 13.8 years, respectively, for the intermediate-risk and high-risk groups. In a subsequent analysis of 891 patients with ET, age >60 years, history of thrombosis, cardiovascular risk factors, and presence of JAK2 V617F mutation retained their prognostic significance regarding thrombosis risk in multivariable analysis. Thus, a modified prognostic model (IPSET-Thrombosis) including cardiovascular risk factors and presence of JAK2 V617F mutation status as additional risk factors was developed to stratify patients into the same 3 groups with significantly different thrombosis-free survival: 87% after 15-year follow-up for low-risk patients and 50% after 7-year follow-up for high-risk patients. In the intermediate-risk group, the thrombosis-free survival rate for the first 10 years was closer to that of the low-risk group and then progressively reached the high-risk survival rate in the subsequent 5 years.

Further analysis of the IPSET-thrombosis showed that among the low-risk patients, the risk of thrombosis was significantly lower in patients with JAK2 negative/unmutated ET in the absence of cardiovascular risk factors (0.44%) compared to the risk of thrombosis in patients with JAK2 unmutated ET in the presence of cardiovascular risk factors (1.05%). The risk of thrombosis in presence of JAK2 mutation without cardiovascular risk factors and in the presence of both JAK2 mutation and cardiovascular risk factors were 1.59% and 2.57%, respectively. These findings led to the development of revised IPSET-thrombosis that stratifies patients into 4 different risk groups: very low risk (age ≤60 years, no prior history of thrombosis and no JAK2 mutation); low risk (age ≤60 years, no prior history of thrombosis and JAK2 mutation); intermediate risk (age >60 years, no prior history of thrombosis and no JAK2 mutation), and high risk (prior history of thrombosis and/or age >60 years with JAK2 mutation). The revised IPSET-thrombosis has also been validated in an independent cohort of 585 patients.

**CALR** mutation status, however, did not have a significant impact on the IPSET-thrombosis prognostic score for predicting the risk of thrombosis. While the incidences of thrombosis were slightly lower in patients with CALR-mutated ET than in those with JAK2-mutated ET, in multivariable analysis, CALR mutation status did not retain the association with the risk of thrombosis in low-risk and intermediate-risk groups. In part, this may be explained by the fact that CALR mutation status tended to cluster with other lower risk features. The significance of CALR mutations and the risk of thrombosis could not be evaluated in the high-risk group since there was a lower proportion of patients with CALR mutation in this group.

**Treatment Options**

**Antiplatelet therapy**

The safety and efficacy of low-dose aspirin for the prevention of thrombotic complications in PV was established in a multicenter trial in patients with no contraindication to aspirin therapy and no history of a thrombotic event (ECLAP study; 518 patients). The use of aspirin resulted in a significant reduction (60%) of combined risk of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major
venous thrombosis, or death from cardiovascular causes ($P = .03$) and the incidence of major bleeding was not significantly increased in the aspirin group. The role of maintaining the hematocrit level <45% in patients receiving treatment was established in the CYTO-PV study.\textsuperscript{177} In this randomized study of 365 patients with PV treated with phlebotomy and/or hydroxyurea, the hematocrit target of <45% resulted in a significantly lower rate of cardiovascular death and major thrombotic events (primary endpoint) than a hematocrit target of 45 to 50%.\textsuperscript{177} After a median follow-up of 31 months, death from cardiovascular causes or major thrombotic events was recorded in 2.7% (5 of 182 patients) of patients with a hematocrit level of <45% compared to 9.8% (18 of 183 patients) of patients with a hematocrit level of 45% to 50% ($P = .007$).

The efficacy of low-dose aspirin for the prevention of thrombosis in patients with ET has not been evaluated in randomized clinical trials. The data supporting the use of aspirin in patients with ET is based on the extrapolation of results from the ECLAP study that evaluated the efficacy of aspirin in patients with PV and the results of retrospective analyses.\textsuperscript{178,179} Results from one retrospective analysis suggest that aspirin may be effective for the prevention of thrombosis in patients with low-risk JAK2-mutated ET and in those with cardiovascular risk factors.\textsuperscript{178} Observation may be appropriate for all other patients with low-risk ET. In this retrospective analysis of 300 patients with low-risk ET managed with aspirin ($n = 198$) or observation ($n = 102$), the incidences of venous thrombosis were higher for those with JAK2 V617F-positive ET not receiving any antiplatelet therapy and patients with cardiovascular risk factors had increased rates of arterial thrombosis while on observation.\textsuperscript{178}

**Cytoreductive Therapy**

Hydroxyurea,\textsuperscript{146,177,180} interferon alfa,\textsuperscript{181-183} and peginterferon alfa\textsuperscript{184-186} have been shown to be effective for the prevention of thrombotic complications in patients with PV.

In a nonrandomized study of 51 patients with PV, the use of hydroxyurea along with phlebotomy as needed significantly reduced the risk of thrombosis compared to a historical control of patients treated with phlebotomy alone.\textsuperscript{180} Long-term follow-up of this study (after a median follow-up of 8.6 years) showed that prolonged use of hydroxyurea was associated with leukemic transformations (5.9% compared to 1.5% for phlebotomy).\textsuperscript{187} However, an analysis from the ECLAP study identified older age and the use of other alkylating agents (eg, P32, busulphan, pipobroman) but not hydroxyurea alone as an independent risk factor for leukemic transformation.\textsuperscript{188} In the randomized trial that compared hydroxyurea and pipobroman as first-line therapy in 285 patients with PV <65 years, the cumulative incidence of leukemic transformation was significantly higher with pipobroman than with hydroxyurea.\textsuperscript{146} At a median follow-up of 15 years the incidences of leukemic transformation were 16.5% and 34%, respectively, for hydroxyurea and pipobroman.

In a randomized, prospective, observational study that included 136 patients with JAK2-mutated PV, interferon alfa-2b resulted in greater molecular response rate (54.7% and 19.4%, respectively; $P < .01$) and 5-year PFS rate (66.3% and 46.7%, respectively; $P < .01$) than hydroxyurea.\textsuperscript{183} In a phase II multicenter study of 40 patients with PV, peginterferon alfa-2a resulted in high rates of complete hematologic response (94.6%) and complete molecular response (24%) with limited toxicity.\textsuperscript{185} At a median follow-up of 31.4 months, 36 patients with a response remained phlebotomy free. A more recent phase II trial that included 43 patients with PV reported a complete hematologic response
rate of 76% and a CMR rate of 18% after a median follow-up of 42 months. The presence of TET2, ASXL1, EZH2, DNMT3A, and IDH1/2 mutations was associated with failure to achieve CMR. Patients with both JAK2 V617F and TET2 mutations at initiation of treatment had a less significant reduction in JAK2 V617F allele burden compared to those with JAK2-mutated/TET2 wild-type disease.

Hydroxyurea, interferon alfa, peginterferon alfa, and possibly anagrelide have been shown to be effective for the prevention of venous thrombotic complications in patients with high-risk ET.

In a study of 114 patients with high-risk ET (>60 years and high risk of thrombosis) randomized to receive hydroxyurea (n = 56) or no myelosuppressive therapy (n = 58), the incidences of thrombotic episodes were significantly lower in patients treated with hydroxyurea (3.6% compared to 24%; P = .003). In another randomized study of 809 patients with high-risk ET, hydroxyurea plus low-dose aspirin was superior to anagrelide plus low-dose aspirin. After a median follow-up of 39 months, the long-term control of platelet counts was equivalent in both groups and anagrelide plus aspirin was better in the prevention of venous thrombosis (P = .006). However, the incidences of arterial thrombosis (P = .004), serious hemorrhage (P = .008), and transformation to MF (P = .01) were higher with anagrelide plus aspirin. In addition, treatment discontinuation rate was also significantly higher with anagrelide plus aspirin. The diagnosis of ET in this trial was based on the Polycythemia Vera Study Group criteria. A more recent phase III randomized study showed that anagrelide was not inferior to hydroxyurea as first-line therapy for the prevention of thrombotic complications in patients with high-risk ET diagnosed according to the WHO criteria. In this study, 259 patients were randomized to either hydroxyurea (n = 122) or anagrelide (n = 137). After a total observation time of 730 patient-years, there was no significant difference between the anagrelide and hydroxyurea in the incidences of arterial or venous thrombotic events, severe bleeding, or rates of discontinuation.

Interferon alfa-2b has been shown to be effective for patients with JAK2-mutated and CALR-mutated ET. In a randomized, prospective, observational study that included 123 patients with ET, the 5-year PFS rate was 75.9% for those with JAK2-mutated ET compared to 47.6% for those without JAK2 mutation (P < .05). In another study of 31 patients, interferon alfa induced high rates of hematologic and molecular responses in CALR-mutated ET. However, the presence of additional mutations (TET2, ASXL1, IDH2, and TP53) was associated with poorer molecular response. In a phase II trial that included 40 patients with ET, peginterferon alfa-2a induced a complete hematologic response rate of 77% and a CMR rate of 17% after a median follow-up of 42 months. The presence of TET2, ASXL1, EZH2, DNMT3A, and IDH1/2 mutations was associated with failure to achieve CMR. Patients with both JAK2 V617F and TET2 mutations at initiation of treatment had a less significant reduction in JAK2 V617F allele burden compared to those with JAK2-mutated or TET2 wild-type disease.

Ongoing randomized clinical trials are evaluating hydroxyurea versus peginterferon alfa-2a or ropeginterferon alfa-2b as initial treatment for high-risk PV and ET.

**Ruxolitinib**

The results of the phase III randomized trial (RESPONSE) confirmed that ruxolitinib is superior to best available therapy (hydroxyurea, interferon or pegylated interferon, pipobroman, anagrelide, lenalidomide, thalidomide, or observation with the use of aspirin) at controlling hematocrit and improving splenomegaly and symptoms in patients with PV. In this study, 222 phlebotomy-dependent patients
with splenomegaly and an inadequate response to or intolerance of hydroxyurea were randomized to receive ruxolitinib (110 patients) or best available therapy (112 patients). The primary endpoint was hematocrit control without phlebotomy and at least a 35% reduction in spleen volume (as assessed by imaging) by 32 weeks. Patients randomized to best available therapy were eligible to cross over to ruxolitinib after 32 weeks if the primary endpoint was not met or if there were signs of disease progression. After 32 weeks, hematocrit control was achieved in 60% of patients treated with ruxolitinib compared to 20% of patients treated with best available therapy. A reduction in spleen volume (≥35%), complete hematologic response, and at least a 50% reduction in symptom burden were achieved in 38%, 24%, and 49% of patients respectively in the ruxolitinib group and in 1%, 9% and 5% of patients, respectively, in the best available therapy group. The incidences of grade 3/4 anemia and herpes zoster infection were higher among patients treated with ruxolitinib (occurring in 2% and 6% of patients, respectively, compared to 0% of patients treated with best available therapy). The 80-week follow-up data confirmed the long-term efficacy of ruxolitinib and the probability of maintaining complete hematologic response for ≥80 weeks was 69%. Ruxolitinib was also associated with a lower rate of thromboembolic events (1.8% and 4.1%, respectively, for patients originally randomized to ruxolitinib and for those receiving ruxolitinib after crossover compared to 8.2% for those receiving best available therapy).

Ruxolitinib has also been shown to be effective for the treatment of PV with an inadequate response to hydroxyurea in patients without splenomegaly. The results of another phase III study showed that ruxolitinib was also effective resulting in improvements in symptoms (although nonsignificant) compared to hydroxyurea in patients with PV that was well-controlled but reported other disease-associated symptoms.

### Treatment Recommendations Based on Risk Stratification

**Polycythemia Vera**

**Low-risk (age <60 years and no prior history of thrombosis)**

Aspirin (81–100 mg/d) and phlebotomy (to maintain hematocrit <45%) is recommended for all patients with low-risk PV. Cytoreductive therapy is not recommended as initial treatment. In the CYTO-PV study, the hematocrit target was the same in both men and women. No thrombotic event was observed in the 66 women with hematocrit of <45% compared to 9 events reported in the 72 women with a hematocrit target of 45% to 50%. However, normal hematocrit levels vary in men (42%–54%) and women (38%–46%). While the target hematocrit level of <45% may be adequate for the majority of patients, there may be situations in which a lower hematocrit cutoff may be appropriate and it should be individualized (eg, 42% for female patients and/or for patients with progressive or residual vascular symptoms).

**High-risk (Age >60 years and/or prior history of thrombosis)**

In addition to aspirin and phlebotomy, cytoreductive therapy is also used to reduce the risk of thrombotic complications for patients with high-risk PV. Cytoreductive therapy (hydroxyurea) with aspirin (81–100 mg/d) for vascular symptoms and phlebotomy (to maintain hematocrit <45%) is recommended as initial treatment. Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b could be considered for younger patients, in pregnant patients requiring cytoreductive therapy,
or in those patients requiring cytoreductive therapy that defer hydroxyurea.

**Essential Thrombocythemia**

**Very-low-risk (Age ≤60 years without JAK2 mutation and no prior history of thrombosis) or Low-risk (Age ≤60 years with JAK2 mutation and no prior history) or Intermediate-risk (Age >60 years, no JAK2 mutation and no prior history of thrombosis)**

As discussed above, the efficacy and safety of low-dose in patients with ET has not been evaluated in randomized clinical trials. The results of a recent systematic review also suggests that the risks and benefit of antiplatelet therapy in patients with ET remains highly uncertain.201 Observation is appropriate for patients with very-low-risk or low-risk ET. Aspirin (81–100 mg/d) could be considered to reduce the risk of thrombotic complications for patients with very-low-risk or low-risk or intermediate risk ET. Aspirin should be used with caution in patients with acquired VWD who have an increased risk of bleeding. In carefully selected patients, twice-daily aspirin at 100-mg dose has been found to be superior to once-daily aspirin (100 mg), a finding that has yet to be confirmed in randomized controlled studies.202 The risk and benefits of higher dose aspirin must be weighed based on the presence of vasomotor symptoms and the risk of bleeding. It may be appropriate in carefully selected patients as clinically indicated.

A report from a more recent retrospective analysis suggests that the use of low-dose aspirin may not be beneficial in patients with low-risk CALR-mutated ET.179 In an analysis that evaluated the benefit-to-risk ratio of low-dose aspirin in 433 patients with low-risk ET (271 patients with CALR mutation and 162 patients with a JAK2 V617F mutation) who were on antiplatelet therapy or observation, low-dose aspirin did not affect the risk of thrombosis but was associated with a higher incidence of bleeding in patients with CALR-mutated ET.179 These findings have to be confirmed in prospective clinical trials. Therefore, at present, the panel felt that there is not enough evidence to recommend withholding aspirin for patients with CALR-mutated ET.

**High-risk (History of thrombosis at any age or >60 years with JAK2 mutation)**

Cytoreductive therapy (hydroxyurea or anagrelide) with aspirin (81–100 mg/d) is recommended as initial treatment. Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b could be considered for younger patients, in pregnant patients requiring cytoreductive therapy, or in those patients requiring cytoreductive therapy that defer hydroxyurea.

**Treatment Response Criteria**

The IWG-MRT and ELN treatment response criteria for PV and ET were first published in 2009 and were revised in 2013.203 Responses are categorized as CR, PR, no response, and PD. The revised response criteria recommend that symptoms should be evaluated by the MPN-SAF TSS. The evaluation of CR or PR includes 4 categories: 1) resolution of disease-related signs and symptoms including palpable splenomegaly and large symptom improvement (≥10-point decrease in MPN-SAF TSS); 2) peripheral blood count response (platelet count ≤400 x 10⁹/L, white blood cell count [WBC] <10 x 10⁹/L, absence of leukoerythroblastosis, and hematocrit <45% without phlebotomies); 3) absence of signs of PD and absence of any hemorrhagic or thrombotic events; and 4) histologic response in bone marrow. Molecular response is not required for the assignment of CR or PR and the revised IWG-MRT and ELN treatment response criteria do not provide a definition of molecular response.
**JAK2V617F Allele Burden**

Long-term ruxolitinib therapy has been shown to reduce JAK2 V617F allele burden in patients with PV that is resistant to hydroxyurea. High JAK2 V617F allele burden has also been reported as a risk factor for myelofibrotic transformation and higher incidences of thrombotic events in patients with PV and ET. These findings suggest that monitoring JAK2 V617F allele burden could be useful to identify patients at higher risk of myelofibrotic transformation. However, the utility of JAK2 V617F allele burden reduction as a predictor of clinical outcome is not well established. In addition, in patients with other mutations in addition to JAK2 mutation, a remission of one mutated clone is not always accompanied by remission of other mutated clones. Therefore, measurement of the JAK2 V617F allele burden is not currently recommended for use in routine clinical practice to guide treatment decisions.

**Monitoring Response and Follow-up Therapy**

The goal of therapy is to prevent thrombotic and hemorrhagic complications without increasing the risk of bleeding. Monitoring for new thrombosis or bleeding, management cardiovascular risk factors, and acquired VWD and/or disease-related major bleeding (in patients with ET) is recommended for all patients. After initiation of low-dose aspirin (and phlebotomy for patients with PV), the guidelines recommend monitoring symptom status using MPN-SAF TSS, signs/symptoms of disease progression, and evaluation for potential indications for cytoreductive therapy every 3 to 6 months or more frequently if clinically indicated. Bone marrow aspirate and biopsy should be performed as clinically indicated (if supported by increased symptoms and signs of progression).

The development of new thrombosis or disease-related major bleeding, frequent or persistent need for phlebotomy, symptomatic or progressive splenomegaly, symptomatic thrombocytosis, progressive leukocytosis, or PD-related symptoms are considered as potential indications for cytoreductive therapy. In one recent retrospective study, the need for ≥3 phlebotomies per year was associated with a significantly higher rate of thrombosis in patients with PV treated with hydroxyurea (20.5% at 3 years compared to 5.3% at 3 years for those receiving ≤2 phlebotomies per year; \( P < .0001 \)). However, these findings could not be confirmed by other investigators. The development of cytopenia (one of the ELN-defined criteria for resistance or intolerance to hydroxyurea) at the lowest dose of hydroxyurea is an adverse prognostic factor associated with higher risk of death and transformation to AML. Patients with high-risk PV or ET treated with cytoreductive therapy as initial treatment should also be monitored for intolerance or resistance to hydroxyurea.

The panel acknowledges that the IWG-MRT and ELN treatment response criteria were developed mainly for use in clinical trials and that clinical benefit may not reach the threshold of the IWG-MRT and ELN response criteria. Response criteria are not defined for patients treated with low-dose aspirin. Available evidence from retrospective studies that have evaluated these response criteria in patients with PV and ET treated with cytoreductive therapy suggests that achievement of CR as outlined in the response criteria did not correlate with a lower incidence of thrombosis or improvement in thrombosis-free survival. In selected patients with a severe thrombotic event, normalization of blood counts might be an essential goal of treatment. While normalization of blood counts after initiation of treatment is usually done in clinical practice, it is not associated with long-term clinical benefit and there is no evidence-based data to recommend a target WBC or platelet count for patients receiving cytoreductive therapy. Response assessment should be done based on the improvement of disease-related...
symptoms at the discretion of the clinician and target WBC or platelet counts should be individualized to prevent new thrombosis or bleeding in each patient depending on the presence of risk factors.

Continuation of prior treatment is recommended for asymptomatic patients (low-risk PV and very-low-risk, low-risk, or intermediate-risk ET) with no potential indications for cytoreductive therapy and for patients with high-risk PV or ET with adequate response to initial cytoreductive therapy. Initiation of cytoreductive therapy is recommended for symptomatic patients with potential indications for cytoreductive therapy.

Ruxolitinib is FDA approved for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. Switching to ruxolitinib (for patients with PV) or alternate cytoreductive therapy (not used before) is recommended for patients with intolerance or with disease that is resistant to hydroxyurea or interferon. Busulfan has also been effective in the treatment of PV and ET that is refractory to hydroxyurea resulting in a complete hematologic response rate of 83% and a PMR rate of 33%.217 However, it is also associated with a significant rate of transformation to AML, and the sequential use of busulphan and hydroxyurea has also been reported to significantly increase the risk of second malignancies.217,218 Therefore, the panel does not recommend the use of busulfan as a treatment option.

Special Considerations in the Management of PV and ET

Management of Thrombosis

The use of clinically appropriate anticoagulant therapy (eg, low-molecular-weight heparin [LMWH], direct oral anticoagulant, warfarin) is recommended for patients with active thrombosis.219-221 The initial use of anticoagulant therapy for the prevention and treatment of thrombosis should be based on the current American College of Chest Physicians Guidelines.219 There are no evidence-based data to guide the selection or appropriate duration of anticoagulation with or without antiplatelet therapy in patients with PV or ET. The duration of anticoagulant therapy is dependent on the severity of the thrombotic event, degree of disease control, and assessment of likelihood of recurrence after cessation of anticoagulant therapy.220 Plateletpheresis may be indicated in patients with ET presenting with acute life-threatening thrombosis or severe bleeding.

Management of Bleeding

It is essential to rule out other potential causes and treat any coexisting causes as necessary. Aspirin should be withheld until bleeding is under control and the use of appropriate cytoreductive therapy should be considered to normalize platelet counts. Coagulation tests to evaluate for acquired VWD (von Willebrand factor activity level) and/or other coagulopathies are recommended for patients undergoing high-risk surgical procedures and those with elevated platelet count and/or splenomegaly or unexplained bleeding. In unanticipated gastrointestinal bleeding, particularly in the setting of splenomegaly, portal hypertension and gastric varices, and special consultation (for endoscopic evaluation) with a hepatologist or a gastrointestinal specialist is recommended.

Surgery

The thrombotic and bleeding risk of the surgical procedure should be strongly considered prior to elective surgery since patients with PV and ET are at higher risk for bleeding despite optimal management. In a retrospective analysis that evaluated the post-surgery outcomes in patients with PV (n= 105) and ET (n=150), although the majority of patients (74%) were treated with cytoreductive therapy and phlebotomy prior to surgery and antithrombotic prophylaxis, a significant proportion of surgeries was complicated by vascular occlusion (7.7%) or major hemorrhage (7.3%). Arterial thrombotic events were more frequent in
patients with ET (5.3% vs. 1.5%; \( P = .08 \)) and venous thrombotic events were more frequent in PV (7.7% vs. 1.1%; \( P = .002 \)). The results of a recent UK prospective cohort study (58 women with a diagnosis of MPN; 47 had a diagnosis of ET) suggest that maternal MPN is associated with higher incidences of maternal complications, preterm delivery, and small for gestational age infants compared to general population. The majority of women (88%) received aspirin and 38% of women additionally received a prophylactic dose of LMWH. Preeclampsia was the most common antenatal complication reported in 9% of women and 22% of neonates were below the 10th percentile for growth. Aggressive intervention for the control of hematocrit, the use of aspirin, and LMWH were associated with significantly better pregnancy outcome in patients with PV.

Evaluation by a high-risk obstetrician should be considered prior to conception. In low-risk pregnancy (no prior ET-related complications, absence of hereditary thrombophilic factors, age <35 years, and platelet count <1000 x 10⁹/L), low-dose aspirin (50–100 mg/d) is recommended throughout pregnancy and for 6 weeks postpartum. Aspirin could be stopped and substituted by LMWH about 2 weeks before labor is expected. In high-risk pregnancy (previous microcirculatory disturbances, presence of 2 or more hereditary thrombophilic factors, severe complications in a previous pregnancy, or age >35 years and platelet count >1000 x 10⁹/L), the use of prophylactic LMWH (subcutaneously) with low-dose aspirin should be considered throughout pregnancy and for 6 weeks postpartum.

Low-dose aspirin should be stopped 1 to 2 weeks prior to delivery and LMWH should be stopped 12 hours to 24 hours before labor is expected. In patients taking LMWH, consultation with a high-risk obstetrician and obstetric anesthesiologist is recommended to determine the optimal timing of discontinuation in preparation for an
epidural prior to delivery. In patients without prior bleeding or thrombotic complications, the use of LMWH instead of low-dose aspirin should be considered in the last 2 weeks of pregnancy and continued until 6 weeks postpartum. Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b should be considered, if cytoreductive therapy is necessary. Hydroxyurea is excreted in breastmilk and should be avoided in women who are breast-feeding. Patients on hydroxyurea prior to pregnancy should be switched to interferons.

Summary

MPN are characterized by a significant symptom burden and a propensity for transformation to MF and then AML. The goal of treatment is to reduce symptom burden and the risk of developing thrombotic and hemorrhagic complications. Regular monitoring of disease-related symptoms, assessment of need for cytoreductive therapy, and appropriate evaluation to rule out disease progression should be an integral part of management of patients with MPN.
References


71. Tefferi A, Siragusana S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both


99. Snyder DS, Palmer J, Stein AS, et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of


